**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 66386

**Manuscript Type:** REVIEW

**SOX transcription factors and glioma stem cells: Choosing between stemness and differentiation**

Stevanovic M *et al*. SOX in glioma stem cells

Milena Stevanovic, Natasa Kovacevic-Grujicic, Marija Mojsin, Milena Milivojevic, Danijela Drakulic

**Milena Stevanovic, Natasa Kovacevic-Grujicic, Marija Mojsin, Milena Milivojevic, Danijela Drakulic,** Laboratory for Human Molecular Genetics, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade 11042, Serbia

**Milena Stevanovic,** Chair Biochemistry and Molecular Biology, Faculty of Biology, University of Belgrade, Belgrade 11158, Serbia

**Milena Stevanovic,** Department of Chemical and Biological Sciences, Serbian Academy of Sciences and Arts, Belgrade 11000, Serbia

**Author contributions:** All authors wrote the manuscript; Stevanovic M and Drakulic D designed the concept of the manuscript; Stevanovic M supervised and edited the manuscript; All authors contributed to the literature review; Stevanovic M, Milivojevic M and Mojsin M contributed to the preparation of the tables; All authors designed the figures; All authors contributed to the article and approved the submitted version.

**Supported by** Ministry of Education, Science and Technological Development of the Republic of Serbia, No. 451-03-9/2021-14/200042.

**Corresponding author: Milena Stevanovic, PhD, Academic Fellow, Full Professor, Senior Research Fellow,** Laboratory for Human Molecular Genetics, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11042 Belgrade 152, Serbia. milenastevanovic@imgge.bg.ac.rs

**Received:** March 26, 2021

**Revised:** July 15, 2021

**Accepted:** September 16, 2021

**Published online:** October 26, 2021

**Abstract**

Glioblastoma (GBM) is the most common, most aggressive and deadliest brain tumor. Recently, remarkable progress has been made towards understanding the cellular and molecular biology of gliomas. GBM tumor initiation, progression and relapse as well as resistance to treatments are associated with glioma stem cells (GSCs). GSCs exhibit a high proliferation rate and self-renewal capacity and the ability to differentiate into diverse cell types, generating a range of distinct cell types within the tumor, leading to cellular heterogeneity. GBM tumors may contain different subsets of GSCs, and some of them may adopt a quiescent state that protects them against chemotherapy and radiotherapy. GSCs enriched in recurrent gliomas acquire more aggressive and therapy-resistant properties, making them more malignant, able to rapidly spread. The impact of SOX transcription factors (TFs) on brain tumors has been extensively studied in the last decade. Almost all *SOX* genes are expressed in GBM, and their expression levels are associated with patient prognosis and survival. Numerous SOX TFs are involved in the maintenance of the stemness of GSCs or play a role in the initiation of GSC differentiation. The fine-tuning of *SOX* gene expression levels controls the balance between cell stemness and differentiation. Therefore, innovative therapies targeting SOX TFs are emerging as promising tools for combatting GBM. Combatting GBM has been a demanding and challenging goal for decades. The current therapeutic strategies have not yet provided a cure for GBM and have only resulted in a slight improvement in patient survival. Novel approaches will require the fine adjustment of multimodal therapeutic strategies that simultaneously target numerous hallmarks of cancer cells to win the battle against GBM.

**Key Words:** Glioblastoma; SOX transcription factors; Glioma stem cells; Stemness; Differentiation

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Stevanovic M, Kovacevic-Grujicic N, Mojsin M, Milivojevic M, Drakulic D. SOX transcription factors and glioma stem cells: Choosing between stemness and differentiation. *World J Stem Cells* 2021; 13(10): 1417-1445

URL: <https://www.wjgnet.com/1948-0210/full/v13/i10/1417.htm>

DOI: <https://dx.doi.org/10.4252/wjsc.v13.i10.1417>

**Core Tip:** Despite the remarkable progress that has been made in understanding the cellular and molecular biology of gliomas, current therapeutic strategies have not yet provided a significant benefit to patients or a cure. This review highlights the key functions of SOX transcriptional factors (TFs) in glioblastoma (GBM) and glioma stem cells (GSCs). SOX TFs influence stemness, self-renewal, proliferation, differentiation, viability, migration, invasion, apoptosis, therapy resistance, sphere-forming capacity and tumorigenicity. We emphasized that fine-tuning of the SOX expression level is required to control the balance between the stemness and differentiation of GSCs, making SOX TFs promising therapeutic targets for combatting GBM.

**INTRODUCTION**

Cancer is among the leading causes of death worldwide, representing a substantial public health burden affecting welfare and life expectancy globally, with enormous impacts on individuals, families and health systems. The global burden of cancer continues to grow with its increasing incidence in the 21st century, mainly due to the growth and ageing of populations, adoption of unhealthy behaviors and exposure to unhealthy environments.

Cancers comprise a large group of diseases that arise from cells that escape the normal checkpoints of cell division and are capable of uncontrolled growth and proliferation. Deregulation of the precise molecular networks operating at the molecular and cellular levels that control cell proliferation, differentiation and cell death leads to the transformation of normal cells into cancer. Despite decades of intensive research, the underlying mechanisms that transform normal cells into cancer cells and enable cancer cells to spread and metastasize other sites in the body, leading to a fatal outcome, are still not completely understood.

The transformation of normal cells into cancer cells is a complex multistep process, and in recent decades, tremendous efforts have been made to understand the underlying mechanisms. In a highly influential article published more than 20 years ago, Hanahan and Weinberg[[1](#_ENREF_1" \o "Hanahan, 2000 #1)] elucidated six essential biological capabilities of cancer cell, widely accepted as the six hallmarks of cancer. Most, if not all, cancers acquire this set of capabilities during the multistep development of human tumors. The six hallmarks of cancer (Figure 1) include cell sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis[[1](#_ENREF_1" \o "Hanahan, 2000 #1)]. Together, these hallmarks constitute an organized framework for interpreting the remarkable diversity of neoplastic diseases[[1](#_ENREF_1" \o "Hanahan, 2000 #1)]. It has been proposed that the genomic instability underlying these hallmarks generates genetic diversity, which contributes to multiple cancer hallmark functions[[1](#_ENREF_1" \o "Hanahan, 2000 #1)].

In subsequent years, remarkable progress was made towards understanding the mechanisms underlying each of the six hallmarks. New technologies and significant advances in the understanding of the cellular and molecular biology of cancer cells provided better insight into the multiple events that allow cancer cells to acquire additional functional capabilities enabling them to survive, proliferate and disseminate. Thus, two additional enabling characteristics of cancer cells-genomic instability and inflammation *via* innate immune cells, have been defined[[2](#_ENREF_2" \o "Hanahan, 2011 #2)]. Genomic instability in cancer cells generates random mutations and acquired genetic diversity, endowing cancer cells with genetic alterations that drive tumor progression[[3](#_ENREF_3" \o "Negrini, 2010 #4)]. Inflammation that fights infections and heals wounds under physiological conditions can assist tumor progression in premalignant and malignant lesions[[4](#_ENREF_4" \o "Colotta, 2009 #5)]. Research on the intersections between inflammation and cancer pathogenesis has provided overwhelming evidence of the essential effects that immune cells, largely of the innate immune system, have on tumor-promoting neoplastic progression[[4-6](#_ENREF_4" \o "Colotta, 2009 #5)].

In an updated article published by Hanahan and Weinberg[[2](#_ENREF_2" \o "Hanahan, 2011 #2)] in 2011, two novel hallmarks were proposed and added to the list of core hallmarks of cancer: reprogramming energy metabolism and evading immune destruction. The first includes the major reprogramming of cellular energy metabolism that is required to support uncontrolled cell proliferation. Since the immune system serves as an important barrier to tumor formation, the second hallmark implicates the ability of cancer cells to evade attack and elimination by immune cells[[2](#_ENREF_2" \o "Hanahan, 2011 #2)].

It has become necessary for the hallmarks of cancer to be revised and upgraded as a result of the progression of cancer research and the accumulation of knowledge over the last decade. Four novel hallmarks of cancer were recently proposed, justified and incorporated into the mainstream hallmark conceptualization. These hallmarks include dedifferentiation and transdifferentiation, epigenetic dysregulation, altered microbiome and altered neuronal signaling (Figure 1)[[7](#_ENREF_7" \o "Senga, 2021 #3)].

**STEM CELLS: DEDIFFERENTIATION AND TRANSDIFFERENTIATION**

Stem cells are defined as cells that have self-renewing capacity and the ability to differentiate into multiple cell types[[8](#_ENREF_8" \o "Weissman, 2000 #8)]. Stem cells are present in mammalian embryos at the blastocyst stage as well as in the tissues and organs of adults. While embryonic stem cells (ESCs) have the ability to differentiate into any cell type present in the adult body, adult stem cells are capable of generating and replacing terminally differentiated cells in specific tissues and are involved in the continual maintenance and repair of tissues and organs throughout life[[9](#_ENREF_9),[10](#_ENREF_10)].

An unidirectional developmental model suggesting that pluripotent stem cells progressively lose their pluripotency as they differentiate along developmental pathways until they reach a terminally differentiated state was widely accepted for several decades[[11](#_ENREF_11" \o "Waddington, 1957 #176)]. It was believed that adult stem cells have the ability to generate only the differentiated cell phenotypes of the tissue in which they reside. At the beginning of the 21st century, numerous studies challenged this strict hierarchy of stem cells and their unidirectional differentiation. The phenomenon of stem cell plasticity, or transdifferentiation, has emerged, suggesting that some adult stem cells have phenotypic potential that extends beyond the cell types of their resident tissue[[12](#_ENREF_12" \o "Krause, 2002 #11),[13](#_ENREF_13)]. It was proposed that some stem cells under specific conditions might diverge from their predetermined pathway and generate cells of a different tissue by entering into a process of transdifferentiation, or that mature cells dedifferentiate into cells with a stem cell phenotype and eventually differentiate into cells of a different tissue[[9](#_ENREF_9" \o "Korbling, 2003 #175)].

In 1962, Gurdon[[14](#_ENREF_14" \o "Gurdon, 1962 #13)] first proposed the hypothesis that the genome of every specialized cell of an adult organism has all the information required to develop into all different cell types. This hypothesis was proven in the seminal publication of Takahashi and Yamanaka[15], which demonstrated that adult differentiated cells could be reprogrammed into induced pluripotent stem cells that have the ability to differentiate into any of the endodermal, ectodermal and mesodermal cell lineages. This reprogramming is achieved by the overexpression of stem cell-associated genes, also known as stemness factors or Yamanaka factors, in the differentiated cells.

These findings validated the phenomenon of dedifferentiation and transdifferentiation, laying the groundwork for cancer stem cell (CSC) theory and the discovery of CSCs.

**CSCs**

The first indication of the existence of cancer cells with a stem cell phenotype came from the study of teratomas, which showed that undifferentiated cells preferably gave rise to nontumorigenic differentiated cells[[16](#_ENREF_16" \o "Kleinsmith, 1964 #15)]. The CSC hypothesis was proposed in line with these data, suggesting that tumors comprise a mixture of malignant stem cells and their benign counterparts[[17](#_ENREF_17" \o "Pierce, 1988 #16)].

CSCs represent a small subpopulation of tumor cells with the capabilities of self-renewal, differentiation, and tumorigenicity when transplanted into an animal host[[18](#_ENREF_18" \o "Yu, 2012 #17)]. CSCs and stem cells share similar properties, including self-renewal ability, unlimited growth potential, invasiveness and blockade of differentiation (reviewed in[[19](#_ENREF_19)]), whereby indefinite self-renewal capability enables CSCs to initiate and maintain tumor growth.

CSCs were first identified in acute myeloid leukemia[[20](#_ENREF_20)] and subsequently in a wide variety of tumor types, including melanoma, osteosarcoma, leukemia, breast, colorectal, brain, prostate, pancreatic, ovarian, liver and lung cancer[[21-23](#_ENREF_21)].

Advances in whole-genome sequencing have revealed the remarkable genetic complexity of malignant tumors and the presence of subpopulations of cells with distinct genotypes and phenotypes[[24](#_ENREF_24" \o "Fisher, 2013 #23)]. The distinct genotypes of cancer cells within the tumor endow the cells with different biological features and phenotypes, providing the basis for intra- and inter-tumor heterogeneity[[25](#_ENREF_25" \o "Prasetyanti, 2017 #24)]. The CSC model explains this phenotypic and functional heterogeneity among cancer cells[[26-29](#_ENREF_26" \o "Clevers, 2011 #27)].

It has been proposed that CSCs originate from either adult tissue-resident stem cells or from differentiated cells that have been reprogrammed to a pluripotent state by the process of dedifferentiation[[30](#_ENREF_30" \o "Walcher, 2020 #29)]. The CSC hypothesis proposes that many heterogenic cancers are organized in a hierarchical fashion based on the differentiation capacity of the cells comprising the tumor[[31](#_ENREF_31" \o "Cole, 2020 #33)]. It has been suggested that this hierarchical order recapitulates the normal tissue hierarchy established by healthy stem cells. Thus, CSCs generate cellular heterogeneity by imposing a differentiation hierarchy by generating a range of distinct cell types present within the tumor[[26](#_ENREF_26" \o "Clevers, 2011 #27)]. However, the established hierarchy is not permanent, and under specific conditions, could be reversed as terminally differentiated cells become dedifferentiated and regain CSC properties[[22](#_ENREF_22" \o "Medema, 2013 #21),[27](#_ENREF_27)].

CSCs have been shown to exhibit high plasticity, resulting in changes in their phenotypic and functional appearance in response to chemo- and radiotherapeutics that cause alterations in the tumor microenvironment (TME)[[30](#_ENREF_30" \o "Walcher, 2020 #29)]. The negative effects of senescence can directly promote cancer stemness by increasing CSC plasticity, activating stemness pathways in non-CSCs, and promoting senescence escape and subsequent activation of a stemness pathway[[30](#_ENREF_30" \o "Walcher, 2020 #29)].

CSCs share a number of unique features that distinguish them from other tumor cells. CSCs are believed to be responsible for cancer initiation, progression, metastasis, recurrence and drug resistance[[32](#_ENREF_32" \o "Visvader, 2008 #32)]. Epithelial CSCs express many genes/pathways typically associated with normal stem cells (reviewed in[[31](#_ENREF_31" \o "Cole, 2020 #33)]). In many types of tumors, some CSCs acquire epithelial-to-mesenchymal transition profiles through the upregulation of the expression of specific genes driving metastasis. CSCs are suggested to be responsible for drug resistance and cancer relapse due to their ability to self-renew and differentiate into heterogeneous lineages of cancer cells[[33](#_ENREF_33" \o "Phi, 2018 #34)]. Drug resistance has been linked to the ability of CSCs to become quiescent, upregulate the expression of enzymes such as aldehyde dehydrogenase, and upregulate the expression of anti-apoptotic proteins and multidrug resistance pumps that increase chemotherapeutic elimination from cells, resulting in low intracellular drug concentrations[[31](#_ENREF_31" \o "Cole, 2020 #33)].

Accordingly, the majority of CSC features depend on the deregulation of signaling pathways that, in turn, rely on the altered activity of specific transcription factors (TFs).

**SOX TFs AND CSCs**

SOX (Sry-related HMG box) proteins constitute a large family of diverse and well-conserved TFs comprising at least 20 SOX family members in mammals[[34](#_ENREF_34" \o "Schepers, 2002 #35)]. They have been divided into eight distinct groups designated A-H based on their structure, expression profiles and homology (Table 1)[[35](#_ENREF_35" \o "Bowles, 2000 #178)]. The SOXB group is further subdivided into subgroup B1 comprising SOX1, SOX2 and SOX3 and subgroup B2 consisting of SOX14 and SOX21[[36](#_ENREF_36)].

SOX proteins display properties of both classical TFs and architectural components of chromatin (reviewed in[[37](#_ENREF_37" \o "Pevny, 1997 #180)]). SOX TFs possess a 79 amino acid HMG domain that enables their specific DNA binding and additional domains involved in transcriptional regulation (reviewed in[[37](#_ENREF_37" \o "Pevny, 1997 #180)]). SOX TFs exert regulatory functions to activate or repress gene transcription through specific interactions with their partner factor(s) and by establishing contacts with the basic transcription machinery[[38](#_ENREF_38" \o "Kamachi, 2000 #181)].

Several essential roles have been attributed to SOX TFs since their discovery. SOX TFs are a component of a regulatory network and, together with other TFs, signaling pathways, epigenetic modifiers and microRNAs, govern diverse cellular processes during development, such as the maintenance of stem cell pluripotency, cell proliferation, cell fate decisions, germ layer formation and the terminal differentiation of cells into tissues and organs (reviewed in[[39](#_ENREF_39),[40](#_ENREF_40)]). However, the roles of SOX TFs are not limited to development as they also influence cell survival, regeneration and death, and control homeostasis in adult tissues[[41](#_ENREF_41),[42](#_ENREF_42)].

Numerous studies have reported the roles of SOX TFs in the preservation of stem cell characteristics, playing a part of regulatory network required to establish ESCs and to maintain their pluripotent and proliferative state. SOX2, OCT4 (octamer-binding TF 4) and NANOG (named after the mythological Celtic land of the ever-young, “Tir nan Og”)[[43](#_ENREF_43)] comprise the core transcriptional circuit that orchestrates the maintenance of stem cell self-renewal and pluripotency[[44](#_ENREF_44)].

Accumulating evidence has demonstrated that OCT4, SOX2 and NANOG are the core factors in a pluripotency gene network involved in the induction, maintenance and loss of pluripotency (reviewed in[[45](#_ENREF_45" \o "Chen, 2017 #37),[46](#_ENREF_46)]). The state of pluripotency, displaying regulatory flexibility, is supported by a highly interconnected pluripotency gene regulatory network that functionally relies on a set of core pluripotency TFs. The state of pluripotency integrates external signals and exerts control over the decision between self-renewal and differentiation at the transcriptional, post-transcriptional and epigenetic levels[[46](#_ENREF_46" \o "Li, 2017 #36)]. Growing evidence shows that the overexpression of these core stemness-associated TFs occurs in various types of human cancers, and aberrant expression of these TFs is associated with tumor initiation, progression and therapy resistance (reviewed in[[47](#_ENREF_47" \o "Huang, 2020 #38)]). Although core stemness-associated TFs play critical roles in maintaining pluripotency and self-renewal in both ESCs and CSCs, distinct mechanistic functions between them have been proposed[[48](#_ENREF_48)].

Since the first reviews of the involvement of the *SOX* genes in cancer[[49](#_ENREF_49" \o "Dong, 2004 #40)], the roles of particular members of this gene family in the development of multiple cancer types have been extensively studied. It has been shown that *SOX* genes may act as oncogenes, tumor suppressor genes, or both depending on the cellular context (reviewed in[[50](#_ENREF_50),[51](#_ENREF_51)]). Oncogenic SOX TFs are overexpressed in multiple cancer types, exerting their oncogenic function *via* several mechanisms, including the promotion of proliferation, suppression of apoptosis, promotion of metastasis, and maintenance of CSCs[[50](#_ENREF_50),[52-54](#_ENREF_52)].

SOX2 TF is one of the most studied SOX proteins, and during the last decade, aberrant SOX2 expression has been associated with various types of cancer (reviewed in[[55](#_ENREF_55" \o "Grimm, 2020 #47),[56](#_ENREF_56)]). In various tumor types, SOX2 has been linked to cancer stemness, and elevated SOX2 expression has also been associated with chemotherapy resistance[[57](#_ENREF_57)], endothelial-to mesenchymal transition[[58](#_ENREF_58)], promotion of clonogenicity, and *in vivo* tumorigenicity[[57](#_ENREF_57),[59](#_ENREF_59)]. In addition, elevated SOX2 expression in glioblastoma (GBM) is associated with increased cell motility and tumor spreading, and its expression is detected amongst circulating CSC islets[[60-62](#_ENREF_60" \o "Krol, 2018 #53)]. A summary of the various roles that SOX2 plays in cancer is presented in Figure 2.

The impact of SOX proteins on brain tumors has been extensively studied in the last few years, and significant contributions have been made to the understanding of the roles of SOX in the initiation, progression, dedifferentiation and spreading of glioma tumors.

**GBM**

GBM, classified as a grade IV glioma tumor, is the most common and malignant primary brain tumor[[63](#_ENREF_63" \o "Thakkar, 2014 #55)]. GBM accounts for more than 60% of all brain tumors in adults and approximately 45% of all gliomas; the annual incidence of GBM is 3-4 cases per 100000 people[[64-66](#_ENREF_64" \o "Hottinger, 2014 #58)]. The ratio of GBM occurrence is, to some extent, higher in men than in women (1.6:1)[[63](#_ENREF_63" \o "Thakkar, 2014 #55)]. The median overall survival of patients with this type of tumor is approximately 12–15 months[[67](#_ENREF_67" \o "Stupp, 2005 #80)], with a median age at diagnosis of 65 years[[68](#_ENREF_68)]. It has been demonstrated that the 5-year survival rate of GBM is 5.3%[[69](#_ENREF_69" \o "Brennan, 2013 #61)]. It is the most aggressive malignant brain tumor in adults, is among the most vascularized solid tumors (reviewed in[[70](#_ENREF_70),[71](#_ENREF_71)]), consists of heterogeneous cell populations in different phases of differentiation[[72](#_ENREF_72)], and recapitulates most of the hallmarks of cancer, including uncontrolled proliferation, resistance to apoptosis, dysregulation of the cell cycle and angiogenesis (reviewed in[[73](#_ENREF_73)]).

GBMs are defined as primary, arising *de novo*, or secondary, developing from lower-grade glioma tumors (grade II or III astrocytoma) through malignant transformation[[74](#_ENREF_74" \o "Ohgaki, 2007 #66)]. Four clinically relevant subtypes of GBM have been identified based on molecular expression patterns: proneural, neural, classical and mesenchymal[[75](#_ENREF_75" \o "Verhaak, 2010 #67)]. It has been demonstrated that various molecular subclasses can be detected within the same tumor[[76](#_ENREF_76" \o "Sottoriva, 2013 #68)]. It is reported in the literature that the proneural and neural GBM subtypes arise in or near the subventricular zone, while the mesenchymal and classical subtypes occur distal to the subventricular zone (reviewed in[[77](#_ENREF_77" \o "Jovčevska, 2019 #69)]). Furthermore, based on the gene expression proﬁle, Park *et al*[[78](#_ENREF_78" \o "Park, 2019 #70)] identiﬁed three prognostic subtypes of GBM: mitotic (favorable), intermediate and invasive.

GBM persistently communicates with its TME, and the TME contributes to the tumorigenesis and progression of GBM (reviewed in[[79](#_ENREF_79" \o "Schiffer, 2018 #72),[80](#_ENREF_80)]). The GBM TME is extremely heterogeneous, consisting of the extracellular matrix, tumor cells such as glioma stem cells (GSCs), and non-tumor cells, including endothelial cells, pericytes, microglia, immune cells, oligodendrocytes, neurons, astrocytes and myeloid-derived suppressor cells (reviewed in[[81](#_ENREF_81)]). Extracellular vesicles containing soluble proteins, DNA, mRNA and noncoding RNAs enable communication between the GBM and the TME, and these vesicles contribute to angiogenesis, invasion, evasion of apoptosis and resistance to drugs (reviewed in[[82](#_ENREF_82),[83](#_ENREF_83)]). Furthermore, it has been shown that GBM cells communicate by thin membrane channels (tunneling nanotubes), and the results obtained by Valdebenito *et al*[[84](#_ENREF_84)] revealed that these nanotubes mediate the protection of GBM cells from temozolomide (TMZ) and ionizing radiation treatment.

The precise cell of origin of GBM is still a controversial issue. It has been reported in the literature that neural stem cells (NSCs) of the subventricular zone and oligodendrocyte precursor cells represent two major candidates for the GBM cell of origin (Figure 3) (reviewed in[[85](#_ENREF_85)]). Furthermore, several studies proposed that GBM might arise from the malignant transformation of glial and astrocyte precursor cells as well as from the dedifferentiation of astrocytes and neurons (reviewed in[[85-87](#_ENREF_85" \o "Fan, 2019 #77)]).

The current standard therapeutic treatment of GBM includes tumor resection by surgery, followed by radiotherapy and concomitant chemotherapy with TMZ[[67](#_ENREF_67" \o "Stupp, 2005 #80)]. However, GBM still remains incurable and usually recurs due to a high level of intertumoral and intratumoral heterogeneity demonstrated at the histological, cellular and molecular levels (reviewed in[[88-90](#_ENREF_88)]), the presence of GSCs, infiltration into the healthy brain parenchyma, the high rate of migration from the tumor core and the ability to generate secondary tumors (reviewed in[[91](#_ENREF_91)]).

GBM tumor initiation, progression, relapse, and resistance to treatments are associated with GSCs (reviewed in[[92](#_ENREF_92),[93](#_ENREF_93)]), and these cells represent one of the main therapeutic targets.

**ROLE OF *SOX* GENES IN GBM AND CORRELATIONS WITH PROGNOSIS AND SURVIVAL OF PATIENTS**

Almost all members of the *SOX* gene family contribute to the malignant phenotype of GBM by regulating cell proliferation, migration, invasion, apoptosis, stemness, tumorigenicity or angiogenesis. The correlation of *SOX* gene expression levels with patient clinical outcomes has been documented (Table 2).

Various *SOX* genes exert oncogenic properties in GBM. *SOX1* regulates the self-renewal and proliferation of patient-derived cells, tumor initiation and progression[[94](#_ENREF_94" \o "Garcia, 2017 #11)]. The expression of *SOX1* in GBM is higher than that in the normal brain and low-grade glioma and correlates with shorter overall survival[[94](#_ENREF_94" \o "Garcia, 2017 #11)]. *SOX2* is one of the most studied *SOX* genes and is overexpressed in tumor samples from patients with GBM and in GBM cell lines[[95-97](#_ENREF_95)]. *SOX2* gene exerts oncogenic activity in glioma cells[[98](#_ENREF_98" \o "Alonso, 2011 #125)]. High expression levels of SOX2, together with other stem cell markers, are observed in poorly differentiated GBM and are associated with its aggressiveness and poor prognosis[[99-101](#_ENREF_99" \o "Ben-Porath, 2008 #5)]. It has been shown that recurrence of the tumor arises at the original site with a more invasive, aggressive phenotype and that is less sensitive to radiochemotherapy, and exhibits increased *SOX2* expression levels compared to corresponding observations in the primary tumors[[102](#_ENREF_102" \o "Nandeesh, 2018 #20)]. In contrast, there are data showing that *SOX2* expression is decreased in recurrent gliomas in comparison with its expression in primary gliomas and that patients with lower *SOX2* expression have a poor prognosis after receiving chemoradiotherapy[[103](#_ENREF_103" \o "Yu, 2019 #29)]. Furthermore, we have shown that *SOX3* promotes the malignant behavior of GBM cells. *SOX3* affects GBM cell viability, proliferation, migration, invasion, and autophagy, and its high expression does not correlate with the overall survival of patients with GBM[[104](#_ENREF_104" \o "Marjanovic Vicentic, 2019 #134)]. However, another study revealed that higher *SOX3* expression levels in glioma and glioma cell lines correlate with poor outcome[[105](#_ENREF_105" \o "Lu, 2020 #18)]. *SOX9* exhibits oncogenic functions; its silencing reduces proliferative capacity, arrests the cell cycle in the G2/M phase and increases glioma cell apoptosis[[106](#_ENREF_106" \o "Wang, 2012 #27)]. The *SOX*9 gene is also involved in the survival, proliferation and senescence of glioma cells[[107](#_ENREF_107" \o "Aldaz, 2020 #1)]. Compared to the survival time of patients with lower *SOX9* expression, the survival of glioma patients with increased *SOX*9 gene expression is shorter[[106](#_ENREF_106" \o "Wang, 2012 #27),[108](#_ENREF_108)]. In addition, *SOX10* is expressed in gliomas[[109](#_ENREF_109" \o "Bannykh, 2006 #4)] and, together with platelet-derived growth factor B, induces glioma development[[110](#_ENREF_110)]. Moreover, high expression of *SOX10* correlates with reduced overall survival[[111](#_ENREF_111" \o "Jin, 2021 #135)].

Despite the well-established oncogenic activities of some *SOX* genes, others show tumor suppressive properties and are associated with good clinical outcomes. It was shown that *SOX5* expression was high in glioma samples and glioma cell lines compared to the *SOX5* expression in the normal adult brain and that the survival of patients with GBM with IgG antibodies against SOX5 in the sera was significantly prolonged compared to the survival of patients with no IgG antibodies[[112](#_ENREF_112" \o "Ueda, 2007 #26)]. Furthermore, *SOX5* overexpression inhibits clone formation of human glioma cells[[113](#_ENREF_113" \o "Tchougounova, 2009 #24)]. Schlierf *et al*[[114](#_ENREF_114" \o "Schlierf, 2007 #21)] showed that the expression level of *SOX5* in gliomas was the same or lower than that in adult brain tissue. In contrast, Tian *et al*[[115](#_ENREF_115" \o "Tian, 2017 #163)] revealed that high expression of *SOX5* correlates with poor prognosis in patients with GBM. These contradictory data probably arose as a consequence of GBM heterogeneity. Furthermore, it was shown that low *SOX6* expression in patients with GBM contributes to a better survival rate than that in patients who display high *SOX6* expression[[116](#_ENREF_116" \o "Jiang, 2020 #14)]. Functional analyses have shown that *SOX7* acts as a tumor suppressor. It has been demonstrated that *SOX7* represses glioma cell proliferation and migration *in vitro* and suppresses tumor formation *in vivo*[[117](#_ENREF_117" \o "Zhao, 2016 #31)]. It has been reported that *SOX11* is overexpressed in glioma samples[[118](#_ENREF_118" \o "Weigle, 2005 #28)]. Hide *et al*[[119](#_ENREF_119" \o "Hide, 2009 #136)] showed that downregulation of *SOX11* expression is associated with a decrease in the survival of patients with GBM. Another study showed that SOX11, together with neurogenin 2, can reprogram glioma cells into neuron-like cells, inhibiting tumor growth and improving survival[[120](#_ENREF_120" \o "Su, 2014 #23)]. Recent data confirmed the tumor suppressor activity of the *SOX15* gene in glioma tumors. Specifically, *SOX15* overexpression inhibits proliferation and invasion, while its upregulation delays tumor formation *in vivo*[[121](#_ENREF_121" \o "Zhang, 2020 #30)]. Furthermore, it has been demonstrated that *SOX21* acts as a tumor suppressor[[122](#_ENREF_122)] that inhibits *SOX2* expression, induces apoptosis in human glioma cells[[123](#_ENREF_123)] and leads to the differentiation of glioma cells, thus inhibiting glioma progression *in vivo*[[124](#_ENREF_124)]. Moreover, it has been shown that simultaneous ectopic expression of the *SOX5*, *SOX6* and *SOX21* genes in human primary GBM cells induces senescence and apoptosis, thus reducing their malignant potential[[125](#_ENREF_125" \o "Kurtsdotter, 2017 #131)]. Their downregulation increases the capacity of stem cells from the subventricular zone of the mouse brain to form glioma tumors upon encountering oncogenic stimuli[[125](#_ENREF_125" \o "Kurtsdotter, 2017 #131)].

Angiogenesis represents one of the hallmarks of GBM[[126](#_ENREF_126" \o "Xu, 2018 #33)]. Upregulation of *SOX7* expression promotes tumor angiogenesis in a mouse model of high-grade glioma, and its high expression in GBM patients is associated with poor survival and early recurrence[[127](#_ENREF_127" \o "Kim, 2018 #16)]. *SOX13* silencing reduced the tube formation abilities of U87 glioma-exposed endothelial cells[[128](#_ENREF_128" \o "He, 2019 #37)]. Downregulation of SOX17 expression inhibited tumor angiogenesis in a mouse model of high-grade glioma, while no correlation between its expression level and the clinical outcome of patients with GBM was documented[[127](#_ENREF_127" \o "Kim, 2018 #16)].

Some *SOX* genes display both oncogenic and tumor suppressive functions depending on the cellular context. For instance, *SOX4* exerts tumor suppressor activity in glioma cells by inducing GO/G1 cell cycle arrest and inhibiting growth[[129](#_ENREF_129" \o "Zhang, 2014 #34)]. In contrast, this gene is involved in maintaining the stemness of glioma-initiating cells[[130](#_ENREF_130" \o "Ikushima, 2009 #35)]. There are also contradictory data regarding the correlation between *SOX4* expression and the clinical outcome in patients with GBM. Galatro *et al*[[131](#_ENREF_131" \o "Galatro, 2013 #36)] reported that patients with GBM with combined high expression of *ID4*, *SOX4* and *OCT4* exhibited lower survival. On the other hand, Zhang *et al*[[129](#_ENREF_129" \o "Zhang, 2014 #34)] demonstrated that *SOX4* expression is positively correlated with a good prognosis for patients with primary GBM.

Taken together, these reported findings demonstrate that almost all *SOX* genes are expressed in GBM and the expression levels of the majority of these genes are associated with the prognosis and survival of patients with GBM. *SOX*genes that exert oncogenic roles are usually associated with a poor prognosis and shorter survival, making them potential candidates as prognostic biomarkers and future therapeutic targets.

**GSCs**

GSCs were among the first CSCs identified in solid tumors[[132](#_ENREF_132" \o "Singh, 2004 #88)]. GSCs are one of the major contributors to GBM heterogeneity; these cells exhibit a high proliferation rate and self-renewal capacity (reviewed in[[71](#_ENREF_71)]), an ability to differentiate into diverse cell types, the ability to recapitulate a whole tumor (reviewed in[[133](#_ENREF_133)]), enhanced invasive capacity, increased angiogenic potential[[134](#_ENREF_134)] and an ability to initiate tumor growth and progression shortly after the surgical removal of the primary GBM tumor (reviewed in[[92](#_ENREF_92)]). GSCs usually express specific markers, such as CD133 (Prominin 1), CD44, NANOG, SOX2, OCT4, POU class 3 homeobox 2 (POU3F2), MYC proto-oncogene (c-Myc), Spalt Like TF 2 (SALL2) and KAT8 regulatory NSL complex subunit 2[[135](#_ENREF_135),[136](#_ENREF_136)]. It has been reported that GBM cells are able to interconvert between GSC and non-GSC states[[137](#_ENREF_137" \o "Gimple, 2019 #151)]. Additionally, it has been found that a single GBM tumor contains different subsets of GSCs: proneural and mesenchymal[[138](#_ENREF_138" \o "Jin, 2017 #96)].

Numerous studies have demonstrated the importance of signaling pathways in the maintenance of GSC properties, including the Hedgehog (HH)[[139](#_ENREF_139)], Wnt/𝛽-catenin[[140](#_ENREF_140)], NOTCH[[141](#_ENREF_141)], Epidermal growth factor receptor[[142](#_ENREF_142)], Phosphatidylinositol-3-phosphate kinase/AKT/Mammalian target of rapamycin[[143](#_ENREF_143)], Mitogen-activated protein kinase (MAPK)[[144](#_ENREF_144)], Inhibitory kappa B kinase/Nuclear factor-kappa B (NF-𝜅B)[[145](#_ENREF_145)], Transforming growth factor-beta (TGF-β)/Small mothers against decapentaplegic[[130](#_ENREF_130)] and Janus kinase/Signal transducers and activators of transcription (STAT)[[146](#_ENREF_146)] pathways (Figure 4). It has been proposed that the regulation of the GSC phenotype results from a complex interplay between multiple signaling cascades[[143](#_ENREF_143" \o "Nanta, 2019 #28),[147-149](#_ENREF_147)]. Accordingly, targeting several GSC-related signaling pathways at the same time seems to be necessary for the increased efficiency of anticancer treatments. A variety of small-molecule inhibitors of the HH, NOTCH and WNT/β-catenin signaling pathways have been identified/developed, along with inhibitors that target different pathways simultaneously, and the efficacy of some of these inhibitors have been demonstrated in preclinical and clinical studies[[150](#_ENREF_150),[151](#_ENREF_151)].

GSCs are enriched in recurrent gliomas (reviewed in[[152](#_ENREF_152" \o "Codrici, 2016 #113)]), and they form more aggressive and diffuse tumors after intracranial transplantation in athymic nude mice than GSCs originating from the primary tumor of the same patient[[153](#_ENREF_153)]. These factors make GSCs a primary therapeutic target. Cho *et al*[[154](#_ENREF_154" \o "Cho, 2013 #150)] described five methods for targeting GSCs: development of GSC-specific chemotherapeutic agents, application of radiosensitizers, usage of immune cells capable of attacking GSCs, induction of GSC differentiation and gene therapy.

GSCs reside in the perivascular and perinecrotic GBM niches (reviewed in[[79](#_ENREF_79" \o "Schiffer, 2018 #72)]). Perivascular niches contain normal and reactive astrocytes, pericytes, glioma-associated microglia/macrophages, myeloid cells, fibroblasts and normal NSCs in addition to GSCs and tumor cells (reviewed in[[79](#_ENREF_79" \o "Schiffer, 2018 #72)]). GSCs residing in the perivascular niches divide slowly, are resistant to therapy and produce high levels of proangiogenic factors (reviewed in[[155](#_ENREF_155),[156](#_ENREF_156)]). It has been reported that endothelial cells stimulate GSC self-renewal and tumorigenicity; on the other hand, GSCs may regulate and contribute to the tumor vasculature by producing cytokines and chemokines and by transdifferentiating into endothelial cells or pericytes (reviewed in[[157](#_ENREF_157" \o "Jhaveri, 2016 #118)]). Perinecrotic niches contain GSCs around necrotic foci induced by hypoxia (reviewed in[[158](#_ENREF_158" \o "Schiffer, 2018 #119)]). Hypoxia induces signaling pathways that can impact GSC self-renewal, proliferation and invasion (reviewed in[[158](#_ENREF_158" \o "Schiffer, 2018 #119)]). Cells expressing molecular markers of both hypoxia and GSCs (*e.g.*, SOX2, NANOG, CD133) are largely found in perinecrotic niches (reviewed in[[134](#_ENREF_134" \o "Boyd, 2021 #91)]).

***SOX* GENES AND MAINTENANCE OF GSCs PROPERTIES**

It has been reported that *SOX* genes play important roles in the maintenance of GSC properties (Figure 5). Knockdown of *SOX1* expression in GSCs impairs their self-renewal, proliferation, viability and tumor-forming capacity, while *SOX*1 overexpression promotes their malignant phenotype[[94](#_ENREF_94" \o "Garcia, 2017 #11)]. Among the SOX TF family, SOX2 is considered to be the most important player in the maintenance of GSC properties, including their tumorigenicity. Gangemi *et al*[[159](#_ENREF_159" \o "Gangemi, 2009 #121)] demonstrated that silencing the *SOX2* gene in GSCs terminated cell proliferation, consequentially leading to the loss of tumorigenicity. The results obtained by Song *et al*[[160](#_ENREF_160" \o "Song, 2016 #122)] indicate that SOX2 plays a primary role in the regulation of CD133-positive GBM cell tumorigenicity. On the other hand, Cox *et al*[[161](#_ENREF_161" \o "Cox, 2012 #123)] demonstrated that a 3-fold increase in *SOX*2 expression in GBM cells decreases their capacity to proliferate and generate spheres. These results suggest that the level of *SOX*2 expression must be precisely regulated by tumor cells during gliomagenesis. Furthermore, it has been found that co-expression of SOX2, oligodendrocyte TF 2 (OLIG2) and zinc finger E-box binding homeobox 2 is involved in the maintenance of GSCs[[162](#_ENREF_162" \o "Singh, 2017 #124)]. Downregulation of SOX2 expression impairs sphere-forming capacity, self-renewal, viability, proliferation, migratory and invasive capabilities of brain tumor stem cells derived from GBM[[98](#_ENREF_98" \o "Alonso, 2011 #125)]. Furthermore, knockdown of SOX3 expression in GSCs decreases the proliferation, migration and invasion capabilities of these cells and enhances their apoptosis[[163](#_ENREF_163)], while knockdown of SOX4 expression in glioma-initiating cells results in reduced sphere-forming and self-renewal capacities[[130](#_ENREF_130)]. Silencing of *SOX9* leads to inhibition of sphere-forming capacity[[164](#_ENREF_164" \o "Wang, 2018 #128)], while *SOX*9 overexpression increases the sphere-forming capacity of GBM cells and induces the formation of larger tumors[[165](#_ENREF_165" \o "Garros-Regulez, 2016 #129)]. In glioma-initiating cells, inhibition of the midkine/anaplastic lymphoma kinase axis promotes SOX9 degradation, resulting in a decrease in the self-renewal and tumorigenic capacities of glioma-initiating cells[[166](#_ENREF_166" \o "Lopez-Valero, 2020 #130)]. Kurtsdotter *et al*[[125](#_ENREF_125" \o "Kurtsdotter, 2017 #131)] demonstrated that simultaneous forced expression of SOX5, SOX6 and SOX21 factors blocks the tumor-inducing capacity of human primary GBM cells.

**THE ROLES OF *SOX* GENES IN STEMNESS AND DIFFERENTIATION OF GSCs**

It has been reported that SOX TFs have important functions in both the maintenance of the stemness of GSCs and the dedifferentiation of glioma cells (Figure 6). The results obtained by Berezovsky *et al*[[100](#_ENREF_100" \o "Berezovsky, 2014 #132)] indicate that *SOX2* may play a central role in the regulation of dedifferentiation and acquisition of GSC properties. They found that knockdown of *SOX2* expression blocks the dedifferentiation of HF2303 GBM cells and reduces their tumorigenicity. Additionally, downregulation of *SOX2* expression in brain tumor stem cells derived from GBM led to an increase in the expression of differentiation markers[[98](#_ENREF_98" \o "Alonso, 2011 #125)]. Furthermore, it was shown that the TGF-β/SOX4/SOX2 pathway plays a crucial role in the maintenance of stemness and tumorigenicity in glioma-initiating cells[[130](#_ENREF_130" \o "Ikushima, 2009 #35)]. It has been shown that the combination of SOX2, POU3F2, SALL2 and OLIG2, detected in the proneural subtype of GBMs, is able to reprogram differentiated tumor cells into GSCs[[136](#_ENREF_136" \o "Suva, 2014 #93)].

In addition to the overwhelming evidence of the importance of the *SOX2* gene in the maintenance of the stem cell properties of GSCs, it was shown that the other two members of the SOXB1 subgroup also play important roles. Dedifferentiation of GBM cell lines is accompanied by an increase in *SOX1* expression. Additionally, *SOX1* expression was higher in patient-derived GSCs than in conventional glioma cell lines, and after the differentiation of these cells, the levels of SOX1 decreased dramatically[[94](#_ENREF_94" \o "Garcia, 2017 #11)]. Recently, we revealed that *SOX3* expression was higher in patient-derived GSCs, as well as in oncospheres derived from GBM cell lines, compared to *SOX3* expression in their differentiated counterparts, suggesting that *SOX3* expression is associated with the undifferentiated state of GBM cells[[104](#_ENREF_104" \o "Marjanovic Vicentic, 2019 #134)].

Additionally, the roles of other *SOX* genes in the regulation of stemness and differentiation of GSCs have been described. It was found that the number of differentiated cells is increased after SOX4 knockdown in glioma-initiating cells[[130](#_ENREF_130" \o "Ikushima, 2009 #35)]. On the other hand, the expression of *SOX9* is increased in oncospheres derived from GBM cell lines compared to its expression in their differentiated counterparts, and silencing of *SOX9* downregulated the expression of the stem cell markers CD133, NESTIN and SOX2[[164](#_ENREF_164)]. Overexpression of *SOX10* in LN229 GBM cells increased the expression levels of the stemness markers CD133, NESTIN, OCT4, NANOG and CD44[[111](#_ENREF_111)]. On the other hand, *SOX11* overexpression in glioma-initiating cell-like cells and human glioma-initiating cells from malignant glioma blocked their tumorigenic ability by inducing neuronal differentiation[[119](#_ENREF_119" \o "Hide, 2009 #136)]. The results obtained by Wu *et al*[[167](#_ENREF_167" \o "Wu, 2020 #137)] indicate that SOX12 regulates the stemness of GBM cells and that SOX2, CD133, and OCT4 act as downstream effectors of SOX12 in these cells. Additionally, the results obtained by Caglayan *et al*[[124](#_ENREF_124" \o "Caglayan, 2013 #138)] suggest that *SOX21* overexpression decreases the stem-like cell properties of glioma cells and initiates their differentiation *in vivo*.

Together, these reported findings indicate that SOX TFs play important roles in GBM and GSCs. Since GSCs are the main drivers of GBM progression and therapy resistance, further studies are needed to comprehensively delineate the roles of SOX TFs in these cells.

***SOX* GENES AND CHEMO-AND RADIORESISTANCE OF GSCs**

GBM inevitably recurs following the initial therapy as a result of intratumoral heterogeneity and resistance to chemo- and radiotherapy, which are considered to be promoted by GSCs (reviewed in[[133](#_ENREF_133),[156](#_ENREF_156)]). Conventional chemo- and radiotherapies affect the proliferative cells within the tumor, while GSCs successfully evade their effects through multiple intrinsic GSC features and adaptive mechanisms (Figure 7). These mechanisms include enhanced expression of the DNA mismatch repair gene *MGMT* (O6-methylguanine-DNA methyltransferase)[[168](#_ENREF_168)], high expression of drug efflux transporters[[168](#_ENREF_168)], activation of the antiapoptotic pathway[[168](#_ENREF_168)], increased replication stress leading to a constitutively active DNA damage response[[169](#_ENREF_169),[170](#_ENREF_170)] and aberrant activation of multiple signaling pathways, such as Notch, HH, Wnt/𝛽-catenin and NF-κB[[171-174](#_ENREF_171)].

One of the essential features of cancer cells that confers resistance to therapy is their plasticity, *i.e.*, the capability of going through phenotypic changes in response to different environmental signals without genomic alteration. It has been shown that extrinsic factors such as radiation[[175](#_ENREF_175)] or TNF- (tumor necrosis factor ) through activation of the NF-𝜅B pathway[[171](#_ENREF_171)] promote proneural to mesenchymal shift of GSCs leading to a radioresistant phenotype[[171](#_ENREF_171)]. Segerman *et al*[[176](#_ENREF_176" \o "Segerman, 2016 #14)] demonstrated that GBMs contain a heterogeneous population of glioma-initiating cells that exhibit variable levels of resistance to radiation and drugs[[176](#_ENREF_176)]. The observed variations in therapy responses are the result of the slow shifts between the proneural- and mesenchymal-like cell states regulated by the changes in DNA methylation of the cis-regulatory regions of mesenchymal master regulator genes.

Another important mechanism underlying GBM resistance to therapy is the ability of differentiated cancer cells to undergo dedifferentiation into cancer stem-like cells. Auffinger *et al*[[177](#_ENREF_177" \o "Auffinger, 2014 #15)] showed that long-term exposure of glioma cells to clinically relevant doses of TMZ caused the phenotypic switch of non-GSCs towards GSCs that exhibited expression of pluripotency- and stemness-related markers CD133, SOX2, OCT4, and Nestin, a highly infiltrative phenotype and increased chemoresistance. Analyses of the long-term effects of sub-toxic doses of radiation on patient-derived differentiated GBM cells and the phenotypic and molecular changes in GBM towards stemness *in vitro* were demonstrated, including the expression of stem cell markers SOX2, Nestin and OLIG2, as well as increased tumorigenicity *in vivo*[[178](#_ENREF_178" \o "Dahan, 2014 #16)].

Quiescent, slow-cycling CSCs play a critical role in tumor recurrence, as they escape the effects of chemo- and radiotherapy that mostly eradicate proliferative cells in the tumor bulk. TMZ treatment in a transgenic mouse model of glioma demonstrated that recurrent tumors derived from dormant glioma cells exhibited stem cell properties[[179](#_ENREF_179" \o "Chen, 2012 #18)]. Qazi *et al*[[180](#_ENREF_180" \o "Qazi, 2016 #19)] revealed that the combined chemoradiotherapy of primary human GBMs resulted in acquired resistance of brain tumor stem cells, which was accompanied by increased expression of stemness-associated factors SOX2 and BMI1 and an enhanced self-renewal capacity of primary GBM cells.

The roles of the *SOX2* and *SOX9* genes in the chemo- and radioresistance of GSCs have been well documented among the members of the SOX TF family (Figure 8). High expression of *SOX2* in GBM patient-derived CD133-positive GSCs was shown to play a key role in promoting the self-renewal of GSCs, thereby contributing to their drug resistance[[160](#_ENREF_160" \o "Song, 2016 #122)]. Yang *et al*[[181](#_ENREF_181)] showed that the miR-145/OCT4/SOX2 axis plays an important role in the chemoradioresistance of CD133-positive GSCs. Inhibition of stemness factors SOX2 and OCT4 by miR-145 was followed by an increased sensitivity of patient-derived CD133-positive GSCs to TMZ and radiation. The reduced chemoradioresistance of GSCs was also accompanied by a decrease in the expression of a few drug resistance (*MDR1* - multidrug resistance protein 1 and *ABCG2*-ABC subfamily G member 2) and antiapoptotic genes (*Bcl-2* - B-cell lymphoma 2 and *Bcl-xL* - B-cell lymphoma-extra large)[[181](#_ENREF_181)]. Overexpression of *ID-4* (inhibitor of differentiation 4) induced the dedifferentiation of human glioma cells into glioma stem-like cells and downregulated the expression of *SOX2*-repressing miR-9\*, leading to enhanced *SOX2* expression[[182](#_ENREF_182)]. SOX2, as a direct transcriptional regulator, upregulates the expression of ABCC3 and ABCC6 transporters, conferring chemoresistance on ID4-induced glioma stem-like cells and patient-derived GSCs[[182](#_ENREF_182" \o "Jeon, 2011 #22)]. Furthermore, it was revealed that *SOX2* is a direct transcriptional target of Forkhead box M1 (FOXM1) and that the FOXM1/SOX2 axis promotes the stemness and radioresistance of GBM[[183](#_ENREF_183" \o "Lee, 2015 #23)].

A study by Garros-Regulez *et al*[[165](#_ENREF_165" \o "Garros-Regulez, 2016 #129)] demonstrated the correlation between high levels of SOX2 and SOX9 expression and resistance of GSCs to TMZ. The SOX2/SOX9 axis acts downstream of the mTOR signaling pathway and contributes to the observed chemoresistance. The authors proposed pharmacological inhibition of SOX2 by using specific inhibitors of the Sonic Hedgehog (SHH) and mTOR signaling pathways as a promising therapeutic approach to overcome TMZ resistance in a group of GBMs that display high expression levels of SOX2 and SOX9[[165](#_ENREF_165)]. Wang *et al*[[164](#_ENREF_164" \o "Wang, 2018 #128)] uncovered the *PDK1* (pyruvate dehydrogenase kinase 1) gene as a direct target of SOX9 that was shown to play a role in the regulation of GSC self-renewal and resistance to TMZ. The silencing of *SOX9* and inhibition of *PDK1* both reduced the activity of the AKT pathway and sensitized GSCs to TMZ treatment *in vivo*, highlighting the SOX9/PDK1 axis as a new promising target for more efficient GBM therapy. Most recently, Sabelström *et al*[[184](#_ENREF_184" \o "Sabelstrom, 2019 #182)] demonstrated the critical role of the ERK1/2/miR-124/SOX9 axis in triggering the differentiation of stem-like GBM cells towards a neuronal phenotype. Inhibition of ERK1/2 activation by using a MEK inhibitor caused the enhanced expression of miR-124 and a reduction in the expression of its target gene, *SOX9*, consequently leading to decreased tumorigenicity and radioresistance in patient-derived GBM xenografts. These results imply that the induction of neuronal differentiation of GSCs represents a promising therapeutic approach in anti-GBM therapy.

**CONCLUSION**

Combatting GBM has been a demanding and challenging goal for decades. Heterogeneity of cell types within the tumor, the contribution of patient-to-patient variability to the growth, the response to treatment driven by the genomics of each tumor and the transition between proliferative and non-proliferative phases make GBM extremely difficult to treat (reviewed in[[185](#_ENREF_185" \o "Yool, 2020 #139)]). GBM is one of the deadliest cancers, and GBM studies face many challenges, some of which are unique to brain tumors (blood-brain barrier and immunosuppressive environment) and others that are shared with other tumors (tumor heterogeneity at the cellular and molecular levels, plasticity, and the presence of CSCs). One of the most essential hallmarks of GBM is tumor heterogeneity, which has been documented at the histological, cellular and molecular levels. Both intertumor heterogeneity (comprising distinct genetic alterations between different individual tumors) and intratumor heterogeneity (comprising diversity within individual tumors) have been identified in GBM (reviewed in[[90](#_ENREF_90" \o "Friedmann-Morvinski, 2014 #2)]). The heterogeneity of GBM has been defined at multiple molecular levels using-omics technologies. Heterogeneity documented at the genomic and transcriptomic levels enables the molecular classification of histopathologically indistinguishable tumors into different subtypes. An advanced understanding of intratumor heterogeneity has been achieved by single-cell sequencing. Patel *et al*[[186](#_ENREF_186)] performed the first single-cell RNA-seq and confirmed that GBM subtype classifiers are variably expressed across individual cells within a single tumor, while a recent study revealed that malignant cells in GBM exist in four main cellular states that are reminiscent of the canonical neurodevelopmental cell types[[187](#_ENREF_187)]. Another level of heterogeneity is linked to treatment-induced plasticity and temporal heterogeneity. By sequencing exomes of initial low-grade gliomas and recurrent tumors from the same patients, Johnson *et al*[[188](#_ENREF_188" \o "Johnson, 2014 #143)] revealed that at least half of the mutations in the initial tumor were undetected at recurrence in 43% of cases. Recently, a database of initial tumor and tumor recurrence samples from patients assembled by the Glass consortium revealed that 35 out of 222 patients exhibited treatment-related hypermutation at recurrence, while 70% of the cohort had an increased mutational burden after recurrence compared with the mutational burden of their initial tumor[[189](#_ENREF_189" \o "Barthel, 2019 #144)]. Taken together, these findings indicate that GBM heterogeneity provides additional layers of complexity that must be taken into consideration in the development of more effective therapies aimed at improving survival in GBM patients.

Remarkable progress has been made towards understanding the cellular and molecular biology of gliomas in the last decade. Advanced technologies have provided novel insights into multiple events that allow GSCs to acquire functional capabilities, enabling them to survive, proliferate and disseminate.

CSCs are considered to be, at least in part, responsible for drug resistance and cancer relapse due to their ability to self-renew and differentiate into heterogeneous lineages of cancer cells. Accordingly, the eradication of CSCs has become one of the major goals in cancer therapies. However, CSCs are very often therapy-resistant, representing the main obstacle to their eradication. Therapy resistance of CSCs is mediated by many different mechanisms, including the acquisition of dormancy, decreased apoptosis, increased DNA repair and drug efflux capacity, interaction with their supporting microenvironment within the CSC niche and hypoxic stability (reviewed in[[190](#_ENREF_190" \o "Steinbichler, 2018 #145)]). GBM tumors may contain different subsets of GSCs[[138](#_ENREF_138" \o "Jin, 2017 #96)]. GSCs may adopt a quiescent state that protects them from chemotherapy and radiotherapy (reviewed in[[191](#_ENREF_191)]), and these treatments might increase the population of GSCs over time (reviewed in[[192](#_ENREF_192)]). GSCs successfully evade the effects of conventional chemo- and radiotherapies through multiple intrinsic GSC features and adaptive mechanisms (Figure 7). GSCs enriched in recurrent gliomas acquire more aggressive and therapy-resistant properties than GSCs originating from primary tumors that become more malignant and rapidly spread, leading to therapeutic failures[[152](#_ENREF_152),[153](#_ENREF_153),[185](#_ENREF_185)].

All these properties make GSCs a promising but very complex and challenging therapeutic target for GBM treatment. A number of approaches for targeting CSCs have been developed, including inhibition of drug efflux ABC transporters, targeting signaling pathways, the microenvironment and cell surface markers of CSCs, differentiation therapy, immunotherapy and application of radiosensitizers (reviewed in[[133](#_ENREF_133),[193-196](#_ENREF_193)]).

Dedifferentiation of tumor cells into a stem cell-like state is considered an additional source of cellular heterogeneity, pointing to tumor cell plasticity as an important driver of GBM heterogeneity[[90](#_ENREF_90" \o "Friedmann-Morvinski, 2014 #2)]. Gimple *et al*[137] proposed novel advanced therapies that are aimed at targeting tumor cell plasticity conferred by dedifferentiation (reviewed in[[7](#_ENREF_7),[137](#_ENREF_137)]). One of the proposed approaches focuses on blocking dedifferentiation by applying a combination of therapies to prevent early resistance to therapeutics endowed by dedifferentiation and acquired lineage plasticity. Differentiation therapy is a novel approach that aims to target dedifferentiation by enhancing the conversion of dedifferentiated tumor cells towards permanently differentiated cells that are more sensitive to chemotherapy. The final proposed approach is focused on the differentiation of CSCs into harmless cell lineages that lack tumorigenic potency and metastatic potential by applying TFs or small molecules.

Significant conceptual and mechanistic similarities between cellular transformation in cancers and cellular reprogramming and dedifferentiation driven by various stem cell-associated pathways have been revealed[[197](#_ENREF_197" \o "Suva, 2013 #153)]. The master regulators of stemness operate through transcriptional control of various stem cell-associated pathways during cellular reprogramming.

Since cell renewal is an ability that cancer cells must acquire to survive therapeutic treatment and reconstitute the tumor, master regulators of stemness have attracted significant attention in the treatment of GBM. SOX TFs are master regulators of stemness with known essential roles in GBM. Accordingly, SOX proteins and SOX2, in particular, have emerged as one of the major therapeutic targets for GBM. Overwhelming evidence of the importance of the *SOX2* gene in the maintenance of the stem cell properties of GSCs has been revealed. Numerous studies have demonstrated that glioma cells rely on SOX2 to maintain their tumorigenic activity, with GSCs displaying high levels of SOX2 (reviewed in[[198](#_ENREF_198" \o "Garros-Regulez, 2016 #154)]). SOX2 overexpression has been found in approximately 90% of human biopsies in GBM patient samples with enrichment in undifferentiated GSC populations. Downregulation of SOX2 in GSCs impairs cell proliferation and the ability of the cells to form tumors *in vivo*.

It has also been shown that numerous SOX TFs are involved in the maintenance of the stemness of GSCs (SOX1, SOX2, SOX3, SOX4, SOX9, SOX10, SOX12) or play a role in the initiation of GSC differentiation (SOX11 and SOX21). Accordingly, the fine-tuning of *SOX* gene expression levels is associated with the control of the balance between stemness and differentiation.

As outlined in this review, SOX TFs play multiple roles in GSCs. They influence GSC stemness, self-renewal, proliferation, differentiation, viability, migration, invasion, apoptosis, therapy resistance, sphere-forming capacity, and tumorigenicity (Figure 5). Therefore, innovative therapies aimed at targeting SOX TFs, and SOX2 in particular, are emerging as promising tools to combat GBM. These therapeutic approaches include the pharmacological inhibition of signaling pathways involving *SOX* genes[[165](#_ENREF_165),[199](#_ENREF_199),[200](#_ENREF_200)], application of natural and synthetic compounds that control the expression of these genes[[201-204](#_ENREF_201)], inhibition of SOX-DNA binding[[205](#_ENREF_205)], inhibition of ubiquitylation and degradation of the SOX2 transcriptional repressor[[206](#_ENREF_206)], immunotherapy[[207](#_ENREF_207),[208](#_ENREF_208)], epigenetic silencing by miRNAs[[181](#_ENREF_181)], blocking SOX function by peptide aptamers[[209](#_ENREF_209)] and direct transcriptional repression of *SOX* gene expression[[210](#_ENREF_210)] (Figure 9).

Modulation of *SOX* gene expression in GSCs represents an attractive approach to combat GBM. *SOX* gene expression in GSCs might be targeted by applying different approaches. One of the approaches to modulate *SOX* gene expression is treatment with natural plant products. Studies on natural plant products have revealed that they can act as effective antitumor agents[[211](#_ENREF_211" \o "Abbas, 2020 #155)]. Forty-nine per cent of the small molecules approved for tumor treatment between 1940 and 2014 were natural plant products or their derivatives[[211](#_ENREF_211" \o "Abbas, 2020 #155)]. Some of these products have anti-GBM potential alone or in combination with other chemotherapeutics[[211-214](#_ENREF_211" \o "Abbas, 2020 #155)]. Our results revealed that extracts from *Anthrisci cerefolii* and *Ononis spinosa* L. plants have anti-GBM activity[[215](#_ENREF_215),[216](#_ENREF_216)]. Furthermore, it has been reported that nuciferine obtained from the leaves of *N. nucifera* Gaertn. inhibited GBM progression *via* the SOX2/AKT/STAT3/Slug pathway[[201](#_ENREF_201)]. On the other hand, it was found that curcumin, which inhibits the proliferation of glioma cells and induces apoptosis and autophagy, simultaneously induces glioma cells to become stem-like and enhances the expression of SOX2, SOX4 and OCT4[[203](#_ENREF_203)]. In addition to natural plant products, antibiotics such as salinomycin and actinomycin D reduce SOX2 expression in GSCs, indicating that drug repurposing may provide additional options for GBM treatment[[202](#_ENREF_202),[204](#_ENREF_204)].

The expression of *SOX* genes in GSCs could be targeted by pharmacological inhibitors of signaling pathways that regulate GSC properties. Rapamycin, an inhibitor of mTOR complex 1, and cyclopamine, an inhibitor of the SHH pathway, reduced the expression of SOX2 and SOX9 in GBM cell lines[[165](#_ENREF_165" \o "Garros-Regulez, 2016 #129)]. Additionally, *SOX* genes could be targeted by engineered artificial TFs that selectively modulate *SOX* gene expression. Stolzenburg *et al*[[210](#_ENREF_210" \o "Stolzenburg, 2012 #165)] developed zinc finger-based TFs that reduced *SOX2* expression, leading to reduced proliferation and colony formation in breast cancer cells.

Another approach is targeting SOX TFs in GSCs by the delivery of vectors that express miRNAs that were shown to specifically downregulate the expression of SOX proteins in GSCs. For example, the delivery of miRNA-145 to GBM patient-derived CSCs *in vitro* and *in vivo* resulted in the downregulation of the expression of stemness factors SOX2 and OCT4, suppression of tumorigenicity, increased sensitivity to TMZ and radiation and enhanced survival rate of xenotransplant mice when applied in combination with radiotherapy and TMZ[[181](#_ENREF_181)].

GSCs could also be combated by vaccine approaches. It was demonstrated that vaccination of immunocompetent mice with Sox2 peptides significantly delayed tumor development[[207](#_ENREF_207" \o "Favaro, 2014 #166)]. Furthermore, Ueda *et al*[[208](#_ENREF_208" \o "Ueda, 2010 #167)] found that the SOX6 peptide induces SOX6 peptide-specific cytotoxic T lymphocytes, which are able to lyse GSCs derived from GBM.

In the last decade, immunotherapy that engages naturally occurring or genetically engineered oncolytic viruses has provided an additional strategy, especially for the treatment of cancers with poor prognosis, such as GBM. Although oncolytic viruses can infect both normal and cancer cells, they can only replicate in cancer cells[[217](#_ENREF_217" \o "Sayed-Ahmed MZ, 2018 #169)]. Preclinical and clinical trials have pointed to the capability of oncolytic viruses to stimulate antitumor immune responses by recruiting T cells (reviewed in[[218](#_ENREF_218),[219](#_ENREF_219)]). It has been reported that the Zika virus exerts oncolytic activity against GSCs. Compared to Zika virus infection of differentiated GBM cells, the Zika virus preferentially infects and selectively kills GSCs and stem-like cells in a SOX2-dependent manner[[220](#_ENREF_220" \o "Zhu, 2017 #172)]. It has also been reported that an immunotherapeutic approach in gliomas that uses a vesicular stomatitis virus expressing HIF-2a, SOX10 and c-Myc together with checkpoint inhibitors anti-PD1 and anti-CTLA-4 enhances the antitumor response[[221](#_ENREF_221" \o "Cockle, 2016 #173)].

The current therapeutic strategies for GBM have not yet provided a cure and have only resulted in a slight improvement in patient survival. Considering that GBM therapies result in poor outcomes and that GBM treatment is one of the most expensive cancer treatment *per capita* in the United States[[222](#_ENREF_222)], there is a critical need for novel and more effective therapeutic options. Novel approaches to GBM treatment will require the fine-tuning of multimodal therapeutic strategies that simultaneously target numerous hallmarks of cancer cells to win the battle against GBM, one of the deadliest cancers.

**REFERENCES**

1 **Hanahan D**, Weinberg RA. The hallmarks of cancer. *Cell* 2000; **100**: 57-70 [PMID: 10647931 DOI: 10.1016/s0092-8674(00)81683-9]

2 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

3 **Negrini S**, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. *Nat Rev Mol Cell Biol* 2010; **11**: 220-228 [PMID: 20177397 DOI: 10.1038/nrm2858]

4 **Colotta F**, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis* 2009; **30**: 1073-1081 [PMID: 19468060 DOI: 10.1093/carcin/bgp127]

5 **DeNardo DG**, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. *Cancer Metastasis Rev* 2010; **29**: 309-316 [PMID: 20405169 DOI: 10.1007/s10555-010-9223-6]

6 **Grivennikov SI**, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell* 2010; **140**: 883-899 [PMID: 20303878 DOI: 10.1016/j.cell.2010.01.025]

7 **Senga SS**, Grose RP. Hallmarks of cancer-the new testament. *Open Biol* 2021; **11**: 200358 [PMID: 33465324 DOI: 10.1098/rsob.200358]

8 **Weissman IL**. Stem cells: units of development, units of regeneration, and units in evolution. *Cell* 2000; **100**: 157-168 [PMID: 10647940 DOI: 10.1016/s0092-8674(00)81692-x]

9 **Kørbling M**, Estrov Z. Adult stem cells for tissue repair - a new therapeutic concept? *N Engl J Med* 2003; **349**: 570-582 [PMID: 12904523 DOI: 10.1056/NEJMra022361]

10 **Young HE**, Black AC Jr. Adult stem cells. *Anat Rec A Discov Mol Cell Evol Biol* 2004; **276**: 75-102 [PMID: 14699636 DOI: 10.1002/ar.a.10134]

11 **Waddington CH**. The Strategy of the Genes: A Discussion of Some Aspects of Theoretical Biology. London: George Allen and Unwin, 1957 [DOI: 10.4324/9781315765471]

12 **Krause DS**. Plasticity of marrow-derived stem cells. *Gene Ther* 2002; **9**: 754-758 [PMID: 12032704 DOI: 10.1038/sj.gt.3301760]

13 **Poulsom R**, Alison MR, Forbes SJ, Wright NA. Adult stem cell plasticity. *J Pathol* 2002; **197**: 441-456 [PMID: 12115861 DOI: 10.1002/path.1176]

14 **GURDON JB**. Adult frogs derived from the nuclei of single somatic cells. *Dev Biol* 1962; **4**: 256-273 [PMID: 13903027 DOI: 10.1016/0012-1606(62)90043-x]

15 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]

16 **Kleinsmith LJ**, Pierce GB Jr. Multipotentiality of single embryonal carcinoma cells. *Cancer Res* 1964; **24**: 1544-1551 [PMID: 14234000]

17 **Pierce GB**, Speers WC. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. *Cancer Res* 1988; **48**: 1996-2004 [PMID: 2450643]

18 **Yu Z**, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. *Int J Biochem Cell Biol* 2012; **44**: 2144-2151 [PMID: 22981632 DOI: 10.1016/j.biocel.2012.08.022]

19 **Carvalho J**. Cell Reversal From a Differentiated to a Stem-Like State at Cancer Initiation. *Front Oncol* 2020; **10**: 541 [PMID: 32351900 DOI: 10.3389/fonc.2020.00541]

20 **Bonnet D**, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 1997; **3**: 730-737 [PMID: 9212098 DOI: 10.1038/nm0797-730]

21 **Chen W**, Dong J, Haiech J, Kilhoffer MC, Zeniou M. Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy. *Stem Cells Int* 2016; **2016**: 1740936 [PMID: 27418931 DOI: 10.1155/2016/1740936]

22 **Medema JP**. Cancer stem cells: the challenges ahead. *Nat Cell Biol* 2013; **15**: 338-344 [PMID: 23548926 DOI: 10.1038/ncb2717]

23 **Visvader JE**, Lindeman GJ. Cancer stem cells: current status and evolving complexities. *Cell Stem Cell* 2012; **10**: 717-728 [PMID: 22704512 DOI: 10.1016/j.stem.2012.05.007]

24 **Fisher R**, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. *Br J Cancer* 2013; **108**: 479-485 [PMID: 23299535 DOI: 10.1038/bjc.2012.581]

25 **Prasetyanti PR**, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. *Mol Cancer* 2017; **16**: 41 [PMID: 28209166 DOI: 10.1186/s12943-017-0600-4]

26 **Clevers H**. The cancer stem cell: premises, promises and challenges. *Nat Med* 2011; **17**: 313-319 [PMID: 21386835 DOI: 10.1038/nm.2304]

27 **Meacham CE**, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. *Nature* 2013; **501**: 328-337 [PMID: 24048065 DOI: 10.1038/nature12624]

28 **Reya T**, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. *Nature* 2001; **414**: 105-111 [PMID: 11689955 DOI: 10.1038/35102167]

29 **Shackleton M**, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. *Cell* 2009; **138**: 822-829 [PMID: 19737509 DOI: 10.1016/j.cell.2009.08.017]

30 **Walcher L**, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauß A, Blaudszun AR, Yevsa T, Fricke S, Kossatz-Boehlert U. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. *Front Immunol* 2020; **11**: 1280 [PMID: 32849491 DOI: 10.3389/fimmu.2020.01280]

31 **Cole AJ**, Fayomi AP, Anyaeche VI, Bai S, Buckanovich RJ. An evolving paradigm of cancer stem cell hierarchies: therapeutic implications. *Theranostics* 2020; **10**: 3083-3098 [PMID: 32194856 DOI: 10.7150/thno.41647]

32 **Visvader JE**, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer* 2008; **8**: 755-768 [PMID: 18784658 DOI: 10.1038/nrc2499]

33 **Phi LTH**, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, Lee YK, Kwon HY. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. *Stem Cells Int* 2018; **2018**: 5416923 [PMID: 29681949 DOI: 10.1155/2018/5416923]

34 **Schepers GE**, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. *Dev Cell* 2002; **3**: 167-170 [PMID: 12194848 DOI: 10.1016/s1534-5807(02)00223-x]

35 **Bowles J**, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. *Dev Biol* 2000; **227**: 239-255 [PMID: 11071752 DOI: 10.1006/dbio.2000.9883]

36 **Uchikawa M**, Kamachi Y, Kondoh H. Two distinct subgroups of Group B Sox genes for transcriptional activators and repressors: their expression during embryonic organogenesis of the chicken. *Mech Dev* 1999; **84**: 103-120 [PMID: 10473124 DOI: 10.1016/s0925-4773(99)00083-0]

37 **Pevny LH**, Lovell-Badge R. Sox genes find their feet. *Curr Opin Genet Dev* 1997; **7**: 338-344 [PMID: 9229109 DOI: 10.1016/s0959-437x(97)80147-5]

38 **Kamachi Y**, Uchikawa M, Kondoh H. Pairing SOX off: with partners in the regulation of embryonic development. *Trends Genet* 2000; **16**: 182-187 [PMID: 10729834 DOI: 10.1016/s0168-9525(99)01955-1]

39 **Reiprich S**, Wegner M. From CNS stem cells to neurons and glia: Sox for everyone. *Cell Tissue Res* 2015; **359**: 111-124 [PMID: 24894327 DOI: 10.1007/s00441-014-1909-6]

40 **She ZY**, Yang WX. SOX family transcription factors involved in diverse cellular events during development. *Eur J Cell Biol* 2015; **94**: 547-563 [PMID: 26340821 DOI: 10.1016/j.ejcb.2015.08.002]

41 **Mercurio S**, Serra L, Nicolis SK. More than just Stem Cells: Functional Roles of the Transcription Factor Sox2 in Differentiated Glia and Neurons. *Int J Mol Sci* 2019; **20**: 4540 [PMID: 31540269 DOI: 10.3390/ijms20184540]

42 **Pevny L**, Placzek M. SOX genes and neural progenitor identity. *Curr Opin Neurobiol* 2005; **15**: 7-13 [PMID: 15721738 DOI: 10.1016/j.conb.2005.01.016]

43 **Cavaleri F**, Schöler HR. Nanog: a new recruit to the embryonic stem cell orchestra. *Cell* 2003; **113**: 551-552 [PMID: 12787492 DOI: 10.1016/s0092-8674(03)00394-5]

44 **Rodda DJ**, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, Robson P. Transcriptional regulation of nanog by OCT4 and SOX2. *J Biol Chem* 2005; **280**: 24731-24737 [PMID: 15860457 DOI: 10.1074/jbc.M502573200]

45 **Chen CY**, Cheng YY, Yen CY, Hsieh PC. Mechanisms of pluripotency maintenance in mouse embryonic stem cells. *Cell Mol Life Sci* 2017; **74**: 1805-1817 [PMID: 27999898 DOI: 10.1007/s00018-016-2438-0]

46 **Li M**, Belmonte JC. Ground rules of the pluripotency gene regulatory network. *Nat Rev Genet* 2017; **18**: 180-191 [PMID: 28045100 DOI: 10.1038/nrg.2016.156]

47 **Huang T**, Song X, Xu D, Tiek D, Goenka A, Wu B, Sastry N, Hu B, Cheng SY. Stem cell programs in cancer initiation, progression, and therapy resistance. *Theranostics* 2020; **10**: 8721-8743 [PMID: 32754274 DOI: 10.7150/thno.41648]

48 **Liu A**, Yu X, Liu S. Pluripotency transcription factors and cancer stem cells: small genes make a big difference. *Chin J Cancer* 2013; **32**: 483-487 [PMID: 23419197 DOI: 10.5732/cjc.012.10282]

49 **Dong C**, Wilhelm D, Koopman P. Sox genes and cancer. *Cytogenet Genome Res* 2004; **105**: 442-447 [PMID: 15237232 DOI: 10.1159/000078217]

50 **Castillo SD**, Sanchez-Cespedes M. The SOX family of genes in cancer development: biological relevance and opportunities for therapy. *Expert Opin Ther Targets* 2012; **16**: 903-919 [PMID: 22834733 DOI: 10.1517/14728222.2012.709239]

51 **Thu KL**, Becker-Santos DD, Radulovich N, Pikor LA, Lam WL, Tsao MS. SOX15 and other SOX family members are important mediators of tumorigenesis in multiple cancer types. *Oncoscience* 2014; **1**: 326-335 [PMID: 25594027 DOI: 10.18632/oncoscience.46]

52 **Sarkar A**, Hochedlinger K. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. *Cell Stem Cell* 2013; **12**: 15-30 [PMID: 23290134 DOI: 10.1016/j.stem.2012.12.007]

53 **Vervoort SJ**, van Boxtel R, Coffer PJ. The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe? *Oncogene* 2013; **32**: 3397-3409 [PMID: 23246969 DOI: 10.1038/onc.2012.506]

54 **Zhu Y**, Li Y, Jun Wei JW, Liu X. The role of Sox genes in lung morphogenesis and cancer. *Int J Mol Sci* 2012; **13**: 15767-15783 [PMID: 23443092 DOI: 10.3390/ijms131215767]

55 **Grimm D**, Bauer J, Wise P, Krüger M, Simonsen U, Wehland M, Infanger M, Corydon TJ. The role of SOX family members in solid tumours and metastasis. *Semin Cancer Biol* 2020; **67**: 122-153 [PMID: 30914279 DOI: 10.1016/j.semcancer.2019.03.004]

56 **Wuebben EL**, Rizzino A. The dark side of SOX2: cancer - a comprehensive overview. *Oncotarget* 2017; **8**: 44917-44943 [PMID: 28388544 DOI: 10.18632/oncotarget.16570]

57 **Schaefer T**, Wang H, Mir P, Konantz M, Pereboom TC, Paczulla AM, Merz B, Fehm T, Perner S, Rothfuss OC, Kanz L, Schulze-Osthoff K, Lengerke C. Molecular and functional interactions between AKT and SOX2 in breast carcinoma. *Oncotarget* 2015; **6**: 43540-43556 [PMID: 26498353 DOI: 10.18632/oncotarget.6183]

58 **Fang X**, Yoon JG, Li L, Yu W, Shao J, Hua D, Zheng S, Hood L, Goodlett DR, Foltz G, Lin B. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. *BMC Genomics* 2011; **12**: 11 [PMID: 21211035 DOI: 10.1186/1471-2164-12-11]

59 **Bareiss PM**, Paczulla A, Wang H, Schairer R, Wiehr S, Kohlhofer U, Rothfuss OC, Fischer A, Perner S, Staebler A, Wallwiener D, Fend F, Fehm T, Pichler B, Kanz L, Quintanilla-Martinez L, Schulze-Osthoff K, Essmann F, Lengerke C. SOX2 expression associates with stem cell state in human ovarian carcinoma. *Cancer Res* 2013; **73**: 5544-5555 [PMID: 23867475 DOI: 10.1158/0008-5472.CAN-12-4177]

60 **Krol I**, Castro-Giner F, Maurer M, Gkountela S, Szczerba BM, Scherrer R, Coleman N, Carreira S, Bachmann F, Anderson S, Engelhardt M, Lane H, Evans TRJ, Plummer R, Kristeleit R, Lopez J, Aceto N. Detection of circulating tumour cell clusters in human glioblastoma. *Br J Cancer* 2018; **119**: 487-491 [PMID: 30065256 DOI: 10.1038/s41416-018-0186-7]

61 **Mansouri S**, Nejad R, Karabork M, Ekinci C, Solaroglu I, Aldape KD, Zadeh G. Sox2: regulation of expression and contribution to brain tumors. *CNS Oncol* 2016; **5**: 159-173 [PMID: 27230973 DOI: 10.2217/cns-2016-0001]

62 **Schaefer T**, Ramadoss A, Leu S, Tintignac L, Tostado C, Bink A, Schürch C, Müller J, Schärer J, Moffa G, Demougin P, Moes S, Stippich C, Falbo S, Neddersen H, Bucher H, Frank S, Jenö P, Lengerke C, Ritz MF, Mariani L, Boulay JL. Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1. *Brain Pathol* 2019; **29**: 336-350 [PMID: 30403311 DOI: 10.1111/bpa.12670]

63 **Thakkar JP**, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL. Epidemiologic and molecular prognostic review of glioblastoma. *Cancer Epidemiol Biomarkers Prev* 2014; **23**: 1985-1996 [PMID: 25053711 DOI: 10.1158/1055-9965.EPI-14-0275]

64 **Hottinger AF**, Stupp R, Homicsko K. Standards of care and novel approaches in the management of glioblastoma multiforme. *Chin J Cancer* 2014; **33**: 32-39 [PMID: 24384238 DOI: 10.5732/cjc.013.10207]

65 **Ostrom QT**, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS. The epidemiology of glioma in adults: a "state of the science" review. *Neuro Oncol* 2014; **16**: 896-913 [PMID: 24842956 DOI: 10.1093/neuonc/nou087]

66 **Rock K**, McArdle O, Forde P, Dunne M, Fitzpatrick D, O'Neill B, Faul C. A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival? *Br J Radiol* 2012; **85**: e729-e733 [PMID: 22215883 DOI: 10.1259/bjr/83796755]

67 **Stupp R**, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005; **352**: 987-996 [PMID: 15758009 DOI: 10.1056/NEJMoa043330]

68 **Ostrom QT**, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. *Neuro Oncol* 2019; **21**: v1-v100 [PMID: 31675094 DOI: 10.1093/neuonc/noz150]

69 **Brennan CW**, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network. The somatic genomic landscape of glioblastoma. *Cell* 2013; **155**: 462-477 [PMID: 24120142 DOI: 10.1016/j.cell.2013.09.034]

70 **Conroy S**, Wagemakers M, Walenkamp AM, Kruyt FA, den Dunnen WF. Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses. *J Neurooncol* 2017; **131**: 11-20 [PMID: 27633774 DOI: 10.1007/s11060-016-2269-8]

71 **Escamilla-Ramírez A**, Castillo-Rodríguez RA, Zavala-Vega S, Jimenez-Farfan D, Anaya-Rubio I, Briseño E, Palencia G, Guevara P, Cruz-Salgado A, Sotelo J, Trejo-Solís C. Autophagy as a Potential Therapy for Malignant Glioma. *Pharmaceuticals (Basel)* 2020; **13**: 156 [PMID: 32707662 DOI: 10.3390/ph13070156]

72 **Ryskalin L**, Gaglione A, Limanaqi F, Biagioni F, Familiari P, Frati A, Esposito V, Fornai F. The Autophagy Status of Cancer Stem Cells in Gliobastoma Multiforme: From Cancer Promotion to Therapeutic Strategies. *Int J Mol Sci* 2019; **20**: 3824 [PMID: 31387280 DOI: 10.3390/ijms20153824]

73 **Thomas L**, Florio T, Perez-Castro C. Extracellular Vesicles Loaded miRNAs as Potential Modulators Shared Between Glioblastoma, and Parkinson's and Alzheimer's Diseases. *Front Cell Neurosci* 2020; **14**: 590034 [PMID: 33328891 DOI: 10.3389/fncel.2020.590034]

74 **Ohgaki H**, Kleihues P. Genetic pathways to primary and secondary glioblastoma. *Am J Pathol* 2007; **170**: 1445-1453 [PMID: 17456751 DOI: 10.2353/ajpath.2007.070011]

75 **Verhaak RG**, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* 2010; **17**: 98-110 [PMID: 20129251 DOI: 10.1016/j.ccr.2009.12.020]

76 **Sottoriva A**, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C, Tavaré S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. *Proc Natl Acad Sci U S A* 2013; **110**: 4009-4014 [PMID: 23412337 DOI: 10.1073/pnas.1219747110]

77 **Jovčevska I**. Genetic secrets of long-term glioblastoma survivors. *Bosn J Basic Med Sci* 2019; **19**: 116-124 [PMID: 30114377 DOI: 10.17305/bjbms.2018.3717]

78 **Park J**, Shim JK, Yoon SJ, Kim SH, Chang JH, Kang SG. Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma. *Sci Rep* 2019; **9**: 10555 [PMID: 31332251 DOI: 10.1038/s41598-019-47066-y]

79 **Schiffer D**, Annovazzi L, Casalone C, Corona C, Mellai M. Glioblastoma: Microenvironment and Niche Concept. *Cancers (Basel)* 2018; **11**: 5 [PMID: 30577488 DOI: 10.3390/cancers11010005]

80 **Schiffer D**, Annovazzi L, Mazzucco M, Mellai M. The Microenvironment in Gliomas: Phenotypic Expressions. *Cancers (Basel)* 2015; **7**: 2352-2359 [PMID: 26633514 DOI: 10.3390/cancers7040896]

81 **Roberts LM**, Munson J. Modulating microenvironments for treating glioblastoma. *Curr Tissue Microenviron Rep* 2020; **1**: 99-111 [PMID: 33134977 DOI: 10.1007/s43152-020-00010-z]

82 **Matarredona ER**, Pastor AM. Extracellular Vesicle-Mediated Communication between the Glioblastoma and Its Microenvironment. *Cells* 2019; **9**: 96 [PMID: 31906023 DOI: 10.3390/cells9010096]

83 **Simon T**, Jackson E, Giamas G. Breaking through the glioblastoma micro-environment via extracellular vesicles. *Oncogene* 2020; **39**: 4477-4490 [PMID: 32366909 DOI: 10.1038/s41388-020-1308-2]

84 **Valdebenito S**, Audia A, Bhat KPL, Okafo G, Eugenin EA. Tunneling Nanotubes Mediate Adaptation of Glioblastoma Cells to Temozolomide and Ionizing Radiation Treatment. *iScience* 2020; **23**: 101450 [PMID: 32882515 DOI: 10.1016/j.isci.2020.101450]

85 **Fan X**, Xiong Y, Wang Y. A reignited debate over the cell(s) of origin for glioblastoma and its clinical implications. *Front Med* 2019; **13**: 531-539 [PMID: 31313083 DOI: 10.1007/s11684-019-0700-1]

86 **Altmann C**, Keller S, Schmidt MHH. The Role of SVZ Stem Cells in Glioblastoma. *Cancers (Basel)* 2019; **11**: 448 [PMID: 30934929 DOI: 10.3390/cancers11040448]

87 **Matarredona ER**, Pastor AM. Neural Stem Cells of the Subventricular Zone as the Origin of Human Glioblastoma Stem Cells. Therapeutic Implications. *Front Oncol* 2019; **9**: 779 [PMID: 31482066 DOI: 10.3389/fonc.2019.00779]

88 **Aum DJ**, Kim DH, Beaumont TL, Leuthardt EC, Dunn GP, Kim AH. Molecular and cellular heterogeneity: the hallmark of glioblastoma. *Neurosurg Focus* 2014; **37**: E11 [PMID: 25434380 DOI: 10.3171/2014.9.FOCUS14521]

89 **Bonavia R**, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. *Cancer Res* 2011; **71**: 4055-4060 [PMID: 21628493 DOI: 10.1158/0008-5472.CAN-11-0153]

90 **Friedmann-Morvinski D**. Glioblastoma heterogeneity and cancer cell plasticity. *Crit Rev Oncog* 2014; **19**: 327-336 [PMID: 25404148 DOI: 10.1615/critrevoncog.2014011777]

91 **Abadi B**, Ahmadi-Zeidabadi M, Dini L, Vergallo C. Stem cell-based therapy treating glioblastoma multiforme. *Hematol Oncol Stem Cell Ther* 2021; **14**: 1-15 [PMID: 32971031 DOI: 10.1016/j.hemonc.2020.08.001]

92 **Bryukhovetskiy I**, Pak O, Khotimchenko Y, Bryukhovetskiy A, Sharma A, Sharma HS. Personalized therapy and stem cell transplantation for pro-inflammatory modulation of cancer stem cells microenvironment in glioblastoma: Review. *Int Rev Neurobiol* 2020; **151**: 67-98 [PMID: 32448615 DOI: 10.1016/bs.irn.2020.03.002]

93 **Vieira de Castro J**, Gonçalves CS, Hormigo A, Costa BM. Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting. *Int J Mol Sci* 2020; **21**: 5278 [PMID: 32722427 DOI: 10.3390/ijms21155278]

94 **Garcia I**, Aldaregia J, Marjanovic Vicentic J, Aldaz P, Moreno-Cugnon L, Torres-Bayona S, Carrasco-Garcia E, Garros-Regulez L, Egaña L, Rubio A, Pollard S, Stevanovic M, Sampron N, Matheu A. Oncogenic activity of SOX1 in glioblastoma. *Sci Rep* 2017; **7**: 46575 [PMID: 28425506 DOI: 10.1038/srep46575]

95 **Annovazzi L**, Mellai M, Caldera V, Valente G, Schiffer D. SOX2 expression and amplification in gliomas and glioma cell lines. *Cancer Genomics Proteomics* 2011; **8**: 139-147 [PMID: 21518820]

96 **Hong X**, Chedid K, Kalkanis SN. Glioblastoma cell line-derived spheres in serum‑containing medium versus serum-free medium: a comparison of cancer stem cell properties. *Int J Oncol* 2012; **41**: 1693-1700 [PMID: 22922964 DOI: 10.3892/ijo.2012.1592]

97 **Schmitz M**, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, Wehner R, Schackert G, Schackert HK, Fussel M, Bachmann M, Rieber EP, Weigle B. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. *Br J Cancer* 2007; **96**: 1293-1301 [PMID: 17375044 DOI: 10.1038/sj.bjc.6603696]

98 **Alonso MM**, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, Lopez de Munain A, Sampron N, Aramburu A, Tejada-Solís S, Vicente C, Odero MD, Bandrés E, García-Foncillas J, Idoate MA, Lang FF, Fueyo J, Gomez-Manzano C. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. *PLoS One* 2011; **6**: e26740 [PMID: 22069467 DOI: 10.1371/journal.pone.0026740]

99 **Ben-Porath I**, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nat Genet* 2008; **40**: 499-507 [PMID: 18443585 DOI: 10.1038/ng.127]

100 **Berezovsky AD**, Poisson LM, Cherba D, Webb CP, Transou AD, Lemke NW, Hong X, Hasselbach LA, Irtenkauf SM, Mikkelsen T, deCarvalho AC. Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation. *Neoplasia* 2014; **16**: 193-206 [PMID: 24726753 DOI: 10.1016/j.neo.2014.03.006]

101 **Sathyan P**, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder S. Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. *J Neurosci* 2015; **35**: 15097-15112 [PMID: 26558781 DOI: 10.1523/JNEUROSCI.1265-15.2015]

102 **Nandeesh BN**, Naskar S, Shashtri AH, Arivazhagan A, Santosh V. Recurrent Glioblastomas Exhibit Higher Expression of Biomarkers with Stem-like Properties. *J Neurosci Rural Pract* 2018; **9**: 86-91 [PMID: 29456350 DOI: 10.4103/jnrp.jnrp\_417\_17]

103 **Yu W**, Ren X, Hu C, Tan Y, Shui Y, Chen Z, Zhang L, Peng J, Wei Q. Glioma SOX2 expression decreased after adjuvant therapy. *BMC Cancer* 2019; **19**: 1087 [PMID: 31718604 DOI: 10.1186/s12885-019-6292-y]

104 **Marjanovic Vicentic J**, Drakulic D, Garcia I, Vukovic V, Aldaz P, Puskas N, Nikolic I, Tasic G, Raicevic S, Garros-Regulez L, Sampron N, Atkinson MJ, Anastasov N, Matheu A, Stevanovic M. SOX3 can promote the malignant behavior of glioblastoma cells. *Cell Oncol (Dordr)* 2019; **42**: 41-54 [PMID: 30209685 DOI: 10.1007/s13402-018-0405-5]

105 **Lu S**, Yu Z, Zhang X, Sui L. MiR-483 Targeted SOX3 to Suppress Glioma Cell Migration, Invasion and Promote Cell Apoptosis. *Onco Targets Ther* 2020; **13**: 2153-2161 [PMID: 32210581 DOI: 10.2147/OTT.S240619]

106 **Wang L**, He S, Yuan J, Mao X, Cao Y, Zong J, Tu Y, Zhang Y. Oncogenic role of SOX9 expression in human malignant glioma. *Med Oncol* 2012; **29**: 3484-3490 [PMID: 22714060 DOI: 10.1007/s12032-012-0267-z]

107 **Aldaz P**, Otaegi-Ugartemendia M, Saenz-Antoñanzas A, Garcia-Puga M, Moreno-Valladares M, Flores JM, Gerovska D, Arauzo-Bravo MJ, Samprón N, Matheu A, Carrasco-Garcia E. SOX9 promotes tumor progression through the axis BMI1-p21CIP. *Sci Rep* 2020; **10**: 357 [PMID: 31941916 DOI: 10.1038/s41598-019-57047-w]

108 **Gao J**, Zhang JY, Li YH, Ren F. Decreased expression of SOX9 indicates a better prognosis and inhibits the growth of glioma cells by inducing cell cycle arrest. *Int J Clin Exp Pathol* 2015; **8**: 10130-10138 [PMID: 26617720]

109 **Bannykh SI**, Stolt CC, Kim J, Perry A, Wegner M. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. *J Neurooncol* 2006; **76**: 115-127 [PMID: 16205963 DOI: 10.1007/s11060-005-5533-x]

110 **Ferletta M**, Uhrbom L, Olofsson T, Pontén F, Westermark B. Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B--induced gliomagenesis. *Mol Cancer Res* 2007; **5**: 891-897 [PMID: 17855658 DOI: 10.1158/1541-7786.MCR-07-0113]

111 **Jin C**, Zhao J, Zhang ZP, Wu M, Li J, Liu B, Bin Liao X, Liao YX, Liu JP. CircRNA EPHB4 modulates stem properties and proliferation of gliomas via sponging miR-637 and up-regulating SOX10. *Mol Oncol* 2021; **15**: 596-622 [PMID: 33085838 DOI: 10.1002/1878-0261.12830]

112 **Ueda R**, Yoshida K, Kawase T, Kawakami Y, Toda M. Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. *Int J Cancer* 2007; **120**: 1704-1711 [PMID: 17230535 DOI: 10.1002/ijc.22472]

113 **Tchougounova E**, Jiang Y, Bråsäter D, Lindberg N, Kastemar M, Asplund A, Westermark B, Uhrbom L. Sox5 can suppress platelet-derived growth factor B-induced glioma development in Ink4a-deficient mice through induction of acute cellular senescence. *Oncogene* 2009; **28**: 1537-1548 [PMID: 19219070 DOI: 10.1038/onc.2009.9]

114 **Schlierf B**, Friedrich RP, Roerig P, Felsberg J, Reifenberger G, Wegner M. Expression of SoxE and SoxD genes in human gliomas. *Neuropathol Appl Neurobiol* 2007; **33**: 621-630 [PMID: 17961134 DOI: 10.1111/j.1365-2990.2007.00881.x]

115 **Tian R**, Wang J, Yan H, Wu J, Xu Q, Zhan X, Gui Z, Ding M, He J. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis. *Oncogene* 2017; **36**: 5861-5873 [PMID: 28628119 DOI: 10.1038/onc.2017.182]

116 **Jiang L**, Yang H, Chen T, Zhu X, Ye J, Lv K. Identification of HMG-box family establishes the significance of SOX6 in the malignant progression of glioblastoma. *Aging (Albany NY)* 2020; **12**: 8084-8106 [PMID: 32388501 DOI: 10.18632/aging.103127]

117 **Zhao T**, Yang H, Tian Y, Xie Q, Lu Y, Wang Y, Su N, Dong B, Liu X, Wang C, Jiang C, Liu X. SOX7 is associated with the suppression of human glioma by HMG-box dependent regulation of Wnt/β-catenin signaling. *Cancer Lett* 2016; **375**: 100-107 [PMID: 26944317 DOI: 10.1016/j.canlet.2016.02.044]

118 **Weigle B**, Ebner R, Temme A, Schwind S, Schmitz M, Kiessling A, Rieger MA, Schackert G, Schackert HK, Rieber EP. Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. *Oncol Rep* 2005; **13**: 139-144 [PMID: 15583815]

119 **Hide T**, Takezaki T, Nakatani Y, Nakamura H, Kuratsu J, Kondo T. Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation. *Cancer Res* 2009; **69**: 7953-7959 [PMID: 19808959 DOI: 10.1158/0008-5472.CAN-09-2006]

120 **Su Z**, Zang T, Liu ML, Wang LL, Niu W, Zhang CL. Reprogramming the fate of human glioma cells to impede brain tumor development. *Cell Death Dis* 2014; **5**: e1463 [PMID: 25321470 DOI: 10.1038/cddis.2014.425]

121 **Zhang D**, Guo S, Wang H, Hu Y. SOX15 exerts antitumor function in glioma by inhibiting cell proliferation and invasion via downregulation of Wnt/β-catenin signaling. *Life Sci* 2020; **255**: 117792 [PMID: 32416168 DOI: 10.1016/j.lfs.2020.117792]

122 **de la Rocha AM**, Sampron N, Alonso MM, Matheu A. Role of SOX family of transcription factors in central nervous system tumors. *Am J Cancer Res* 2014; **4**: 312-324 [PMID: 25057435]

123 **Ferletta M**, Caglayan D, Mokvist L, Jiang Y, Kastemar M, Uhrbom L, Westermark B. Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells. *Int J Cancer* 2011; **129**: 45-60 [PMID: 20824710 DOI: 10.1002/ijc.25647]

124 **Caglayan D**, Lundin E, Kastemar M, Westermark B, Ferletta M. Sox21 inhibits glioma progression in vivo by forming complexes with Sox2 and stimulating aberrant differentiation. *Int J Cancer* 2013; **133**: 1345-1356 [PMID: 23463365 DOI: 10.1002/ijc.28147]

125 **Kurtsdotter I**, Topcic D, Karlén A, Singla B, Hagey DW, Bergsland M, Siesjö P, Nistér M, Carlson JW, Lefebvre V, Persson O, Holmberg J, Muhr J. SOX5/6/21 Prevent Oncogene-Driven Transformation of Brain Stem Cells. *Cancer Res* 2017; **77**: 4985-4997 [PMID: 28687615 DOI: 10.1158/0008-5472.CAN-17-0704]

126 **Xu Y,** Yuan FE, Chen QX, Liu BH. Molecular mechanisms involved in angiogenesis and potential target of antiangiogenesis in human glioblastomas. *GLIOMA* 2018; **1**: 35-42 [DOI: 10.4103/glioma.glioma\_10\_17]

127 **Kim IK**, Kim K, Lee E, Oh DS, Park CS, Park S, Yang JM, Kim JH, Kim HS, Shima DT, Kim JH, Hong SH, Cho YH, Kim YH, Park JB, Koh GY, Ju YS, Lee HK, Lee S, Kim I. Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality. *J Exp Med* 2018; **215**: 963-983 [PMID: 29444818 DOI: 10.1084/jem.20170123]

128 **He Z**, Ruan X, Liu X, Zheng J, Liu Y, Liu L, Ma J, Shao L, Wang D, Shen S, Yang C, Xue Y. FUS/circ\_002136/miR-138-5p/SOX13 feedback loop regulates angiogenesis in Glioma. *J Exp Clin Cancer Res* 2019; **38**: 65 [PMID: 30736838 DOI: 10.1186/s13046-019-1065-7]

129 **Zhang J**, Jiang H, Shao J, Mao R, Liu J, Ma Y, Fang X, Zhao N, Zheng S, Lin B. SOX4 inhibits GBM cell growth and induces G0/G1 cell cycle arrest through Akt-p53 axis. *BMC Neurol* 2014; **14**: 207 [PMID: 25366337 DOI: 10.1186/s12883-014-0207-y]

130 **Ikushima H**, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. *Cell Stem Cell* 2009; **5**: 504-514 [PMID: 19896441 DOI: 10.1016/j.stem.2009.08.018]

131 **Galatro TF**, Uno M, Oba-Shinjo SM, Almeida AN, Teixeira MJ, Rosemberg S, Marie SK. Differential expression of ID4 and its association with TP53 mutation, SOX2, SOX4 and OCT-4 expression levels. *PLoS One* 2013; **8**: e61605 [PMID: 23613880 DOI: 10.1371/journal.pone.0061605]

132 **Singh SK**, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. *Nature* 2004; **432**: 396-401 [PMID: 15549107 DOI: 10.1038/nature03128]

133 **Auffinger B**, Spencer D, Pytel P, Ahmed AU, Lesniak MS. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. *Expert Rev Neurother* 2015; **15**: 741-752 [PMID: 26027432 DOI: 10.1586/14737175.2015.1051968]

134 **Boyd NH**, Tran AN, Bernstock JD, Etminan T, Jones AB, Gillespie GY, Friedman GK, Hjelmeland AB. Glioma stem cells and their roles within the hypoxic tumor microenvironment. *Theranostics* 2021; **11**: 665-683 [PMID: 33391498 DOI: 10.7150/thno.41692]

135 **Ferreyra Solari NE**, Belforte FS, Canedo L, Videla-Richardson GA, Espinosa JM, Rossi M, Serna E, Riudavets MA, Martinetto H, Sevlever G, Perez-Castro C. The NSL Chromatin-Modifying Complex Subunit KANSL2 Regulates Cancer Stem-like Properties in Glioblastoma That Contribute to Tumorigenesis. *Cancer Res* 2016; **76**: 5383-5394 [PMID: 27406830 DOI: 10.1158/0008-5472.CAN-15-3159]

136 **Suvà ML**, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. *Cell* 2014; **157**: 580-594 [PMID: 24726434 DOI: 10.1016/j.cell.2014.02.030]

137 **Gimple RC**, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. *Genes Dev* 2019; **33**: 591-609 [PMID: 31160393 DOI: 10.1101/gad.324301.119]

138 **Jin X**, Kim LJY, Wu Q, Wallace LC, Prager BC, Sanvoranart T, Gimple RC, Wang X, Mack SC, Miller TE, Huang P, Valentim CL, Zhou QG, Barnholtz-Sloan JS, Bao S, Sloan AE, Rich JN. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. *Nat Med* 2017; **23**: 1352-1361 [PMID: 29035367 DOI: 10.1038/nm.4415]

139 **Clement V**, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. *Curr Biol* 2007; **17**: 165-172 [PMID: 17196391 DOI: 10.1016/j.cub.2006.11.033]

140 **Kim KH**, Seol HJ, Kim EH, Rheey J, Jin HJ, Lee Y, Joo KM, Lee J, Nam DH. Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. *Neuro Oncol* 2013; **15**: 161-171 [PMID: 23258844 DOI: 10.1093/neuonc/nos299]

141 **Fan X**, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, Nikkhah G, Dimeco F, Piccirillo S, Vescovi AL, Eberhart CG. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. *Stem Cells* 2010; **28**: 5-16 [PMID: 19904829 DOI: 10.1002/stem.254]

142 **Soeda A**, Inagaki A, Oka N, Ikegame Y, Aoki H, Yoshimura S, Nakashima S, Kunisada T, Iwama T. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. *J Biol Chem* 2008; **283**: 10958-10966 [PMID: 18292095 DOI: 10.1074/jbc.M704205200]

143 **Nanta R**, Shrivastava A, Sharma J, Shankar S, Srivastava RK. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells. *Mol Cell Biochem* 2019; **454**: 11-23 [PMID: 30251117 DOI: 10.1007/s11010-018-3448-z]

144 **Riddick G**, Kotliarova S, Rodriguez V, Kim HS, Linkous A, Storaska AJ, Ahn S, Walling J, Belova G, Fine HA. A Core Regulatory Circuit in Glioblastoma Stem Cells Links MAPK Activation to a Transcriptional Program of Neural Stem Cell Identity. *Sci Rep* 2017; **7**: 43605 [PMID: 28256619 DOI: 10.1038/srep43605]

145 **Rinkenbaugh AL**, Cogswell PC, Calamini B, Dunn DE, Persson AI, Weiss WA, Lo DC, Baldwin AS. IKK/NF-κB signaling contributes to glioblastoma stem cell maintenance. *Oncotarget* 2016; **7**: 69173-69187 [PMID: 27732951 DOI: 10.18632/oncotarget.12507]

146 **Almiron Bonnin DA**, Havrda MC, Lee MC, Liu H, Zhang Z, Nguyen LN, Harrington LX, Hassanpour S, Cheng C, Israel MA. Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia. *Oncogene* 2018; **37**: 1107-1118 [PMID: 29155422 DOI: 10.1038/onc.2017.404]

147 **Jin X**, Yin J, Kim SH, Sohn YW, Beck S, Lim YC, Nam DH, Choi YJ, Kim H. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. *Cancer Res* 2011; **71**: 7125-7134 [PMID: 21975932 DOI: 10.1158/0008-5472.CAN-11-1330]

148 **Peñuelas S**, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. *Cancer Cell* 2009; **15**: 315-327 [PMID: 19345330 DOI: 10.1016/j.ccr.2009.02.011]

149 **Sunayama J**, Matsuda K, Sato A, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. *Stem Cells* 2010; **28**: 1930-1939 [PMID: 20857497 DOI: 10.1002/stem.521]

150 **Yang L**, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F, Cui H. Targeting cancer stem cell pathways for cancer therapy. *Signal Transduct Target Ther* 2020; **5**: 8 [PMID: 32296030 DOI: 10.1038/s41392-020-0110-5]

151 **Yang Y**, Li X, Wang T, Guo Q, Xi T, Zheng L. Emerging agents that target signaling pathways in cancer stem cells. *J Hematol Oncol* 2020; **13**: 60 [PMID: 32456660 DOI: 10.1186/s13045-020-00901-6]

152 **Codrici E**, Enciu AM, Popescu ID, Mihai S, Tanase C. Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets. *Stem Cells Int* 2016; **2016**: 5728438 [PMID: 26977157 DOI: 10.1155/2016/5728438]

153 **Huang Q**, Zhang QB, Dong J, Wu YY, Shen YT, Zhao YD, Zhu YD, Diao Y, Wang AD, Lan Q. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. *BMC Cancer* 2008; **8**: 304 [PMID: 18940013 DOI: 10.1186/1471-2407-8-304]

154 **Cho DY**, Lin SZ, Yang WK, Lee HC, Hsu DM, Lin HL, Chen CC, Liu CL, Lee WY, Ho LH. Targeting cancer stem cells for treatment of glioblastoma multiforme. *Cell Transplant* 2013; **22**: 731-739 [PMID: 23594862 DOI: 10.3727/096368912X655136]

155 **Brooks MD**, Sengupta R, Snyder SC, Rubin JB. Hitting Them Where They Live: Targeting the Glioblastoma Perivascular Stem Cell Niche. *Curr Pathobiol Rep* 2013; **1**: 101-110 [PMID: 23766946 DOI: 10.1007/s40139-013-0012-0]

156 **Prager BC**, Bhargava S, Mahadev V, Hubert CG, Rich JN. Glioblastoma Stem Cells: Driving Resilience through Chaos. *Trends Cancer* 2020; **6**: 223-235 [PMID: 32101725 DOI: 10.1016/j.trecan.2020.01.009]

157 **Jhaveri N**, Chen TC, Hofman FM. Tumor vasculature and glioma stem cells: Contributions to glioma progression. *Cancer Lett* 2016; **380**: 545-551 [PMID: 25527451 DOI: 10.1016/j.canlet.2014.12.028]

158 **Schiffer D**, Mellai M, Bovio E, Bisogno I, Casalone C, Annovazzi L. Glioblastoma niches: from the concept to the phenotypical reality. *Neurol Sci* 2018; **39**: 1161-1168 [PMID: 29736738 DOI: 10.1007/s10072-018-3408-0]

159 **Gangemi RM**, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. *Stem Cells* 2009; **27**: 40-48 [PMID: 18948646 DOI: 10.1634/stemcells.2008-0493]

160 **Song WS**, Yang YP, Huang CS, Lu KH, Liu WH, Wu WW, Lee YY, Lo WL, Lee SD, Chen YW, Huang PI, Chen MT. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. *J Chin Med Assoc* 2016; **79**: 538-545 [PMID: 27530866 DOI: 10.1016/j.jcma.2016.03.010]

161 **Cox JL**, Wilder PJ, Desler M, Rizzino A. Elevating SOX2 levels deleteriously affects the growth of medulloblastoma and glioblastoma cells. *PLoS One* 2012; **7**: e44087 [PMID: 22937156 DOI: 10.1371/journal.pone.0044087]

162 **Singh DK**, Kollipara RK, Vemireddy V, Yang XL, Sun Y, Regmi N, Klingler S, Hatanpaa KJ, Raisanen J, Cho SK, Sirasanagandla S, Nannepaga S, Piccirillo S, Mashimo T, Wang S, Humphries CG, Mickey B, Maher EA, Zheng H, Kim RS, Kittler R, Bachoo RM. Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma. *Cell Rep* 2017; **18**: 961-976 [PMID: 28122245 DOI: 10.1016/j.celrep.2016.12.064]

163 **Su R**, Cao S, Ma J, Liu Y, Liu X, Zheng J, Chen J, Liu L, Cai H, Li Z, Zhao L, He Q, Xue Y. Knockdown of SOX2OT inhibits the malignant biological behaviors of glioblastoma stem cells via up-regulating the expression of miR-194-5p and miR-122. *Mol Cancer* 2017; **16**: 171 [PMID: 29132362 DOI: 10.1186/s12943-017-0737-1]

164 **Wang Z**, Xu X, Liu N, Cheng Y, Jin W, Zhang P, Wang X, Yang H, Liu H, Tu Y. SOX9-PDK1 axis is essential for glioma stem cell self-renewal and temozolomide resistance. *Oncotarget* 2018; **9**: 192-204 [PMID: 29416606 DOI: 10.18632/oncotarget.22773]

165 **Garros-Regulez L**, Aldaz P, Arrizabalaga O, Moncho-Amor V, Carrasco-Garcia E, Manterola L, Moreno-Cugnon L, Barrena C, Villanua J, Ruiz I, Pollard S, Lovell-Badge R, Sampron N, Garcia I, Matheu A. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. *Expert Opin Ther Targets* 2016; **20**: 393-405 [PMID: 26878385 DOI: 10.1517/14728222.2016.1151002]

166 **López-Valero I**, Dávila D, González-Martínez J, Salvador-Tormo N, Lorente M, Saiz-Ladera C, Torres S, Gabicagogeascoa E, Hernández-Tiedra S, García-Taboada E, Mendiburu-Eliçabe M, Rodríguez-Fornés F, Sánchez-Domínguez R, Segovia JC, Sánchez-Gómez P, Matheu A, Sepúlveda JM, Velasco G. Midkine signaling maintains the self-renewal and tumorigenic capacity of glioma initiating cells. *Theranostics* 2020; **10**: 5120-5136 [PMID: 32308772 DOI: 10.7150/thno.41450]

167 **Wu B**, Yang C, Fang Y, Ding W, Zhang Y. Long noncoding RNA DUXAP10 promotes the stemness of glioma cells by recruiting HuR to enhance Sox12 mRNA stability. *Environ Toxicol* 2021; **36**: 840-849 [PMID: 33340249 DOI: 10.1002/tox.23087]

168 **Liu G**, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. *Mol Cancer* 2006; **5**: 67 [PMID: 17140455 DOI: 10.1186/1476-4598-5-67]

169 **Bao S**, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 2006; **444**: 756-760 [PMID: 17051156 DOI: 10.1038/nature05236]

170 **Carruthers RD**, Ahmed SU, Ramachandran S, Strathdee K, Kurian KM, Hedley A, Gomez-Roman N, Kalna G, Neilson M, Gilmour L, Stevenson KH, Hammond EM, Chalmers AJ. Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells. *Cancer Res* 2018; **78**: 5060-5071 [PMID: 29976574 DOI: 10.1158/0008-5472.CAN-18-0569]

171 **Bhat KPL**, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape K. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. *Cancer Cell* 2013; **24**: 331-346 [PMID: 23993863 DOI: 10.1016/j.ccr.2013.08.001]

172 **Hsieh A**, Ellsworth R, Hsieh D. Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells. *J Cell Physiol* 2011; **226**: 1118-1127 [PMID: 20857406 DOI: 10.1002/jcp.22433]

173 **Kim Y**, Kim KH, Lee J, Lee YA, Kim M, Lee SJ, Park K, Yang H, Jin J, Joo KM, Lee J, Nam DH. Wnt activation is implicated in glioblastoma radioresistance. *Lab Invest* 2012; **92**: 466-473 [PMID: 22083670 DOI: 10.1038/labinvest.2011.161]

174 **Wang J**, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA. Notch promotes radioresistance of glioma stem cells. *Stem Cells* 2010; **28**: 17-28 [PMID: 19921751 DOI: 10.1002/stem.261]

175 **Halliday J**, Helmy K, Pattwell SS, Pitter KL, LaPlant Q, Ozawa T, Holland EC. In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. *Proc Natl Acad Sci U S A* 2014; **111**: 5248-5253 [PMID: 24706837 DOI: 10.1073/pnas.1321014111]

176 **Segerman A**, Niklasson M, Haglund C, Bergström T, Jarvius M, Xie Y, Westermark A, Sönmez D, Hermansson A, Kastemar M, Naimaie-Ali Z, Nyberg F, Berglund M, Sundström M, Hesselager G, Uhrbom L, Gustafsson M, Larsson R, Fryknäs M, Segerman B, Westermark B. Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition. *Cell Rep* 2016; **17**: 2994-3009 [PMID: 27974212 DOI: 10.1016/j.celrep.2016.11.056]

177 **Auffinger B**, Tobias AL, Han Y, Lee G, Guo D, Dey M, Lesniak MS, Ahmed AU. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. *Cell Death Differ* 2014; **21**: 1119-1131 [PMID: 24608791 DOI: 10.1038/cdd.2014.31]

178 **Dahan P**, Martinez Gala J, Delmas C, Monferran S, Malric L, Zentkowski D, Lubrano V, Toulas C, Cohen-Jonathan Moyal E, Lemarie A. Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. *Cell Death Dis* 2014; **5**: e1543 [PMID: 25429620 DOI: 10.1038/cddis.2014.509]

179 **Chen J**, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell population propagates glioblastoma growth after chemotherapy. *Nature* 2012; **488**: 522-526 [PMID: 22854781 DOI: 10.1038/nature11287]

180 **Qazi MA**, Vora P, Venugopal C, McFarlane N, Subapanditha MK, Murty NK, Hassell JA, Hallett RM, Singh SK. A novel stem cell culture model of recurrent glioblastoma. *J Neurooncol* 2016; **126**: 57-67 [PMID: 26498281 DOI: 10.1007/s11060-015-1951-6]

181 **Yang YP**, Chien Y, Chiou GY, Cherng JY, Wang ML, Lo WL, Chang YL, Huang PI, Chen YW, Shih YH, Chen MT, Chiou SH. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. *Biomaterials* 2012; **33**: 1462-1476 [PMID: 22098779 DOI: 10.1016/j.biomaterials.2011.10.071]

182 **Jeon HM**, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, Kim H. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9\*-mediated suppression of SOX2. *Cancer Res* 2011; **71**: 3410-3421 [PMID: 21531766 DOI: 10.1158/0008-5472.CAN-10-3340]

183 **Lee Y**, Kim KH, Kim DG, Cho HJ, Kim Y, Rheey J, Shin K, Seo YJ, Choi YS, Lee JI, Lee J, Joo KM, Nam DH. FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2. *PLoS One* 2015; **10**: e0137703 [PMID: 26444992 DOI: 10.1371/journal.pone.0137703]

184 **Sabelström H,** Petri R, Shchors K, Jandial R, Schmidt C, Sacheva R, Masic S, Yuan E, Fenster T, Martinez M, Saxena S, Nicolaides TP, Ilkhanizadeh S, Berger MS, Snyder EY, Weiss WA, Jakobsson J, Persson AI. Driving Neuronal Differentiation through Reversal of an ERK1/2-miR-124-SOX9 Axis Abrogates Glioblastoma Aggressiveness. Cell Rep 2019; 28: 2064-2079, e11 [PMID: 31433983 DOI: 10.1016/j.celrep.2019.07.071]

185 **Yool AJ**, Ramesh S. Molecular Targets for Combined Therapeutic Strategies to Limit Glioblastoma Cell Migration and Invasion. *Front Pharmacol* 2020; **11**: 358 [PMID: 32292341 DOI: 10.3389/fphar.2020.00358]

186 **Patel AP**, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science* 2014; **344**: 1396-1401 [PMID: 24925914 DOI: 10.1126/science.1254257]

187 **Neftel C**, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suvà ML. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. *Cell* 2019; **178**: 835-849.e21 [PMID: 31327527 DOI: 10.1016/j.cell.2019.06.024]

188 **Johnson BE**, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJM, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. *Science* 2014; **343**: 189-193 [PMID: 24336570 DOI: 10.1126/science.1239947]

189 **Barthel FP**, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW; GLASS Consortium. Longitudinal molecular trajectories of diffuse glioma in adults. *Nature* 2019; **576**: 112-120 [PMID: 31748746 DOI: 10.1038/s41586-019-1775-1]

190 **Steinbichler TB**, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova II. Therapy resistance mediated by cancer stem cells. *Semin Cancer Biol* 2018; **53**: 156-167 [PMID: 30471331 DOI: 10.1016/j.semcancer.2018.11.006]

191 **Fidoamore A**, Cristiano L, Antonosante A, d'Angelo M, Di Giacomo E, Astarita C, Giordano A, Ippoliti R, Benedetti E, Cimini A. Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance. *Stem Cells Int* 2016; **2016**: 6809105 [PMID: 26880981 DOI: 10.1155/2016/6809105]

192 **Garnier D**, Renoult O, Alves-Guerra MC, Paris F, Pecqueur C. Glioblastoma Stem-*Like* Cells, Metabolic Strategy to Kill a Challenging Target. *Front Oncol* 2019; **9**: 118 [PMID: 30895167 DOI: 10.3389/fonc.2019.00118]

193 **Bindra RS**, Chalmers AJ, Evans S, Dewhirst M. GBM radiosensitizers: dead in the water…or just the beginning? *J Neurooncol* 2017; **134**: 513-521 [PMID: 28762004 DOI: 10.1007/s11060-017-2427-7]

194 **Cho Y**, Kim YK. Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance. *Front Oncol* 2020; **10**: 764 [PMID: 32582535 DOI: 10.3389/fonc.2020.00764]

195 **Ghosh D**, Nandi S, Bhattacharjee S. Combination therapy to checkmate Glioblastoma: clinical challenges and advances. *Clin Transl Med* 2018; **7**: 33 [PMID: 30327965 DOI: 10.1186/s40169-018-0211-8]

196 **Weenink B**, French PJ, Sillevis Smitt PAE, Debets R, Geurts M. Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. *Cancers (Basel)* 2020; **12**: 751 [PMID: 32235752 DOI: 10.3390/cancers12030751]

197 **Suvà ML**, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. *Science* 2013; **339**: 1567-1570 [PMID: 23539597 DOI: 10.1126/science.1230184]

198 **Garros-Regulez L**, Garcia I, Carrasco-Garcia E, Lantero A, Aldaz P, Moreno-Cugnon L, Arrizabalaga O, Undabeitia J, Torres-Bayona S, Villanua J, Ruiz I, Egaña L, Sampron N, Matheu A. Targeting SOX2 as a Therapeutic Strategy in Glioblastoma. *Front Oncol* 2016; **6**: 222 [PMID: 27822457 DOI: 10.3389/fonc.2016.00222]

199 **Hägerstrand D**, He X, Bradic Lindh M, Hoefs S, Hesselager G, Ostman A, Nistér M. Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. *Neuro Oncol* 2011; **13**: 1178-1191 [PMID: 21940738 DOI: 10.1093/neuonc/nor113]

200 **Singh S**, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. *Mol Cancer* 2012; **11**: 73 [PMID: 23009336 DOI: 10.1186/1476-4598-11-73]

201 **Li Z**, Chen Y, An T, Liu P, Zhu J, Yang H, Zhang W, Dong T, Jiang J, Zhang Y, Jiang M, Yang X. Nuciferine inhibits the progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug signaling pathway. *J Exp Clin Cancer Res* 2019; **38**: 139 [PMID: 30922391 DOI: 10.1186/s13046-019-1134-y]

202 **Magrath JW**, Raney WR, Kim Y. In vitro demonstration of salinomycin as a novel chemotherapeutic agent for the treatment of SOX2‑positive glioblastoma cancer stem cells. *Oncol Rep* 2020; **44**: 777-785 [PMID: 32627023 DOI: 10.3892/or.2020.7642]

203 **Shi L**, Wang Z, Sun G. Curcumin induces glioma stem-like cell formation. *Neuroreport* 2015; **26**: 167-172 [PMID: 25602852 DOI: 10.1097/WNR.0000000000000320]

204 **Taylor JT**, Ellison S, Pandele A, Wood S, Nathan E, Forte G, Parker H, Zindy E, Elvin M, Dickson A, Williams KJ, Karabatsou K, McCabe M, McBain C, Bigger BW. Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma. *Neuro Oncol* 2020; **22**: 1289-1301 [PMID: 32227096 DOI: 10.1093/neuonc/noaa051]

205 **Taniguchi J**, Pandian GN, Hidaka T, Hashiya K, Bando T, Kim KK, Sugiyama H. A synthetic DNA-binding inhibitor of SOX2 guides human induced pluripotent stem cells to differentiate into mesoderm. *Nucleic Acids Res* 2017; **45**: 9219-9228 [PMID: 28934500 DOI: 10.1093/nar/gkx693]

206 **Yin Y**, Xie CM, Li H, Tan M, Chen G, Schiff R, Xiong X, Sun Y. The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells. *Proc Natl Acad Sci U S A* 2019; **116**: 20528-20538 [PMID: 31548378 DOI: 10.1073/pnas.1905973116]

207 **Favaro R**, Appolloni I, Pellegatta S, Sanga AB, Pagella P, Gambini E, Pisati F, Ottolenghi S, Foti M, Finocchiaro G, Malatesta P, Nicolis SK. Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. *Cancer Res* 2014; **74**: 1833-1844 [PMID: 24599129 DOI: 10.1158/0008-5472.CAN-13-1942]

208 **Ueda R**, Ohkusu-Tsukada K, Fusaki N, Soeda A, Kawase T, Kawakami Y, Toda M. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. *Int J Cancer* 2010; **126**: 919-929 [PMID: 19728337 DOI: 10.1002/ijc.24851]

209 **Liu K**, Xie F, Zhao T, Zhang R, Gao A, Chen Y, Li H, Zhang S, Xiao Z, Li J, Hong X, Shang L, Huang W, Wang J, El-Rifai W, Zaika A, Chen X, Que J, Lan X. Targeting SOX2 Protein with Peptide Aptamers for Therapeutic Gains against Esophageal Squamous Cell Carcinoma. *Mol Ther* 2020; **28**: 901-913 [PMID: 31991109 DOI: 10.1016/j.ymthe.2020.01.012]

210 **Stolzenburg S**, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, Strahl BD, Blancafort P. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. *Nucleic Acids Res* 2012; **40**: 6725-6740 [PMID: 22561374 DOI: 10.1093/nar/gks360]

211 **Abbas MN**, Kausar S, Cui H. Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations. *Clin Transl Oncol* 2020; **22**: 963-977 [PMID: 31630356 DOI: 10.1007/s12094-019-02227-3]

212 **Kuete V**, Sandjo LP, Ouete JL, Fouotsa H, Wiench B, Efferth T. Cytotoxicity and modes of action of three naturally occurring xanthones (8-hydroxycudraxanthone G, morusignin I and cudraxanthone I) against sensitive and multidrug-resistant cancer cell lines. *Phytomedicine* 2014; **21**: 315-322 [PMID: 24075210 DOI: 10.1016/j.phymed.2013.08.018]

213 **Ramachandran C**, Portalatin G, Quirin KW, Escalon E, Khatib Z, Melnick SJ. Inhibition of AKT signaling by supercritical CO2 extract of mango ginger (Curcuma amada Roxb.) in human glioblastoma cells. *J Complement Integr Med* 2015; **12**: 307-315 [PMID: 26439597 DOI: 10.1515/jcim-2015-0005]

214 **Suresh D**, Srinivasan K. Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats. *Indian J Med Res* 2010; **131**: 682-691 [PMID: 20516541]

215 **Stojković D**, Drakulić D, Gašić U, Zengin G, Stevanović M, Rajčević N, Soković M. Ononis spinosa L, an edible and medicinal plant: UHPLC-LTQ-Orbitrap/MS chemical profiling and biological activities of the herbal extract. *Food Funct* 2020; **11**: 7138-7151 [PMID: 32749435 DOI: 10.1039/d0fo01595d]

216 **Stojković D**, Drakulić D, Schwirtlich M, Rajčević N, Stevanović M, Soković MD, Gašić U. Extract of *Herba Anthrisci cerefolii*: Chemical Profiling and Insights into Its Anti-Glioblastoma and Antimicrobial Mechanism of Actions. *Pharmaceuticals (Basel)* 2021; **14**: 55 [PMID: 33445425 DOI: 10.3390/ph14010055]

217 **Sayed-Ahmed MZ MH,** Elsherbini MM, Syed NK, Shoeib SM. Oncolytic Viruses: A gene Therapy for Treatment of Cancer in Companion Animals. *Health Sci J* 2018; **12**: 579 [DOI: 10.21767/1791-809X.1000579]

218 **Sostoa J**, Dutoit V, Migliorini D. Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors. *Int J Mol Sci* 2020; **21**: 7449 [PMID: 33050329 DOI: 10.3390/ijms21207449]

219 **Stavrakaki E**, Dirven CMF, Lamfers MLM. Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response. *Cancers (Basel)* 2021; **13**: 614 [PMID: 33557101 DOI: 10.3390/cancers13040614]

220 **Zhu Z**, Gorman MJ, McKenzie LD, Chai JN, Hubert CG, Prager BC, Fernandez E, Richner JM, Zhang R, Shan C, Tycksen E, Wang X, Shi PY, Diamond MS, Rich JN, Chheda MG. Zika virus has oncolytic activity against glioblastoma stem cells. *J Exp Med* 2017; **214**: 2843-2857 [PMID: 28874392 DOI: 10.1084/jem.20171093]

221 **Cockle JV**, Rajani K, Zaidi S, Kottke T, Thompson J, Diaz RM, Shim K, Peterson T, Parney IF, Short S, Selby P, Ilett E, Melcher A, Vile R. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. *Neuro Oncol* 2016; **18**: 518-527 [PMID: 26409567 DOI: 10.1093/neuonc/nov173]

222 **Perry J**, Okamoto M, Guiou M, Shirai K, Errett A, Chakravarti A. Novel therapies in glioblastoma. *Neurol Res Int* 2012; **2012**: 428565 [PMID: 22530121 DOI: 10.1155/2012/428565]

223 **Schaefer T**, Lengerke C. SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond. *Oncogene* 2020; **39**: 278-292 [PMID: 31477842 DOI: 10.1038/s41388-019-0997-x]

224 **Agnihotri S**, Burrell KE, Wolf A, Jalali S, Hawkins C, Rutka JT, Zadeh G. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. *Arch Immunol Ther Exp (Warsz)* 2013; **61**: 25-41 [PMID: 23224339 DOI: 10.1007/s00005-012-0203-0]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflict of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** Serbian Academy of Sciences and Arts, Full member; National Council for Scientific and Technological Development of the Republic of Serbia, Vice-president; Serbian Society for Molecular Biology, Steering Committee member; Serbian Neuroscience Society, Steering Committee member

**Peer-review started:** March 26, 2021

**First decision:** July 4, 2021

**Article in press:** September 16, 2021

**Specialty type:** Biochemistry and molecular biology

**Country/Territory of origin:** Serbia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Cenciarelli C **S-Editor:** Liu M **L-Editor:** A **P-Editor:** Yu HG


**Figure Legends**




**Figure 1 Historical overview of the hallmarks of cancer.** Hallmarks of cancer proposed by Hanahan and Weinberg[1,2] in 2000 and 2011 are presented in yellow and blue colors, respectively. Additional hallmarks of cancer proposed by Senga and Grose[3] in 2021 are presented in pink.




**Figure 2** **The roles of the SOX2 transcription factor in cancer.** Modified from[[223](#_ENREF_223" \o "Schaefer, 2020 #54)].




**Figure 3 Potential cells of origin of glioblastoma.** During the neural differentiation process (black arrows), neural stem cells differentiate into fate-restricted precursors that are capable of differentiating into neurons, astrocytes or oligodendrocytes. Glioblastoma cells can arise due to the accumulation of cancer driver mutations in different cell types or due to the dedifferentiation of mature cells (orange arrows). Modified from[[224](#_ENREF_224)]. References are included in the main text.




**Figure 4 Signaling pathways involved in the maintenance of** **glioma stem cell properties.** The main signaling pathways involved in the maintenance of glioma stem cell properties include Hedgehog, Wnt/𝛽-catenin, NOTCH, Epidermal growth factor receptor, Phosphatidylinositol-3-phosphate kinase/AKT/Mammalian target of rapamycin, Mitogen-activated protein kinase, Inhibitory kappa B kinase/Nuclear factor-kappa B, Transforming growth factor-beta/Small mothers against decapentaplegic and Janus kinase/Signal transducers and activators of transcription. References are included in the main text. MAPK: Mitogen-activated protein kinase; JAK/STAT: Janus kinase/Signal transducers and activators of transcription; EGFR: Epidermal growth factor receptor; PI3K/AKT/mTOR: Phosphatidylinositol-3-phosphate kinase/AKT/Mammalian target of rapamycin; IKK/NF-𝜅B: Inhibitory kappa B kinase/Nuclear factor-kappa B; TGF-β/SMAD: Transforming growth factor-beta/Small mothers against decapentaplegic; GSCs: Glioma stem cells.




**Figure 5 The roles of SOX** **transcription factors in glioma stem cells.** SOX transcription factors exert numerous functions in glioma stem cells (GSCs). They influence GSC self-renewal, stemness, tumorigenicity, sphere-forming capacity, proliferation rate, viability, migration and invasion capacities, and apoptosis. Some of the members of the *SOX* gene family are involved in the resistance of GSCs to therapy. Blue arrows represent stimulation, and orange bars represent inhibition. References are included in the main text. GSCs: Glioma stem cells.




**Figure 6 SOX transcription factors involved in the maintenance of stemness and differentiation of glioma stem cells.** References are included in the main text.

****

**Figure 7 Mechanisms of chemo- and radioresistance of glioma stem cells.** A: O6-methylguanine-DNA methyltransferase (MGMT) repair; B: Overexpression of drug efflux transporters; C: Enhanced antiapoptotic pathway; D: Increased replicative stress and DNA damage response. Efficient DNA repair; E: Dysregulated signaling pathways; F: Proneural-to-mesenchymal transition; G: Dedifferentiation to GSC; H: Glioma stem cells (GSC) quiescence. Resistance of GSCs to temozolomide is achieved through increased expression of MGMT, drug efflux transporters and antiapoptotic proteins. Replicative stress, constitutively active DNA damage response and efficient DNA repair confer radioresistance to GSCs. Aberrantly activated signaling pathways, the ability of non-GSC tumor cells to dedifferentiate, proneural-to-mesenchymal transition and the capacity of GSCs to become quiescent contribute to the chemo- and radioresistance of glioblastoma. References are included in the main text. RT: radiation; O6-MeG: O-6-methylguanine; GSC: Glioma stem cell; TMZ: Temozolomide.



**Figure 8** **Schematic illustration of the involvement of SOX2 and SOX9 in the chemoresistance and radioresistance of glioma stem cells.** The expression of stemness-related transcription factor SOX2 is elevated in glioma stem cells (GSCs) through various mechanisms (decreased expression of miR-145 and miR-9\* that directly target *SOX2*, direct transcriptional activation by Forkhead box M1 and through mammalian target of rapamycin signaling) contributing to chemo- and radioresistance of GSCs. SOX2 directly activates the expression of ABCC3 and ABCC6 transporters. mTOR signaling affects the SOX2/SOX9 axis, contributing to chemoresistance. The ERK1/2/miR-124/SOX9 axis and direct targeting of *PDK1* ***(***pyruvate dehydrogenase kinase 1)by SOX9 have a role in resistance to radiation and temozolomide, respectively. References are included in the main text. GSCs: Glioma stem cells; FOXM1: Forkhead box M1; mTOR: Mammalian target of rapamycin; PDK1: Pyruvate dehydrogenase kinase 1.



**Figure 9 Overview of the therapeutic strategies for targeting *SOX* in glioma stem cells.** References are included in the main text. GSCs: Glioma stem cells.

**Table 1 Classification of the human *SOX* genes[**[**35**](#_ENREF_35)**]**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| *SOXA* | *SOXB* | | *SOXC* | *SOXD* | *SOXE* | *SOXF* | *SOXG* | *SOXH* |
|  | *SOXB1* | *SOXB2* |  |  |  |  |  |  |
| *SRY* | *SOX1* | *SOX14* | *SOX4* | *SOX5* | *SOX8* | *SOX7* | *SOX15* | *SOX30* |
|  | *SOX2* | *SOX21* | *SOX11* | *SOX6* | *SOX9* | *SOX17* |  |  |
|  | *SOX3* |  | *SOX12* | *SOX13* | *SOX10* | *SOX18* |  |  |

**Table 2 *SOX* gene activity in glioblastoma and correlation with the clinical outcome of glioblastoma patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Ref.** | **Gene** | **Activity** | **Clinical outcome** |
| [[94](#_ENREF_94)] | *SOX1* | Oncogenic | Poor |
| [[98-101](#_ENREF_98)] | *SOX2* | Oncogenic | Poor |
| [104, 105] | *SOX3* | Possible oncogenic | No correlation /poor |
| [[129-131](#_ENREF_129)] | *SOX4* | Oncogenic in glioma-initiating cells; tumor suppressor in GBM | Poor/good |
| [115, 125] | *SOX5* | Tumor suppressor | Poor |
| [116, 125] | *SOX6* | Tumor suppressor | Poor |
| [117, 127] | *SOX7* | Tumor suppressor; glioma angiogenesis | Poor |
| [[106-108](#_ENREF_106)] | *SOX9* | Oncogenic | Poor |
| [110, 111] | *SOX10* | Possible oncogenic | Poor |
| [[119](#_ENREF_119)] | *SOX11* | Tumor suppressor | Good |

Glioblastoma: GBM.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**